

BMJ Open

Longitudinal follow up of employment status in patients with chronic fatigue syndrome after mononucleosis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005798
Article Type:	Research
Date Submitted by the Author:	28-May-2014
Complete List of Authors:	Nyland, Morten; Haukeland Universiyt Hospital, Neurology Naess, Halvor; Haukeland University Hospital, Neurology Birkeland, Jon; Haukeland Universiyt Hospital, Neurology Nyland, Harald; Haukeland Universiyt Hospital, Neurology
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Health economics, Infectious diseases
Keywords:	Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Infectious disease/HIV < NEUROLOGY, OCCUPATIONAL & INDUSTRIAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 Longitudinal follow up of employment status in patients with chronic
4 fatigue syndrome after mononucleosis
5
6
7
8

9 **Morten Nyland¹ cand. polit., Halvor Naess^{12*} MD, Jon Steinar Birkeland² MD, Harald**
10 **Nyland¹ MD**
11

12
13
14
15 ¹ Institute of clinical medicine, University of Bergen, Bergen, Norway

16
17 ² Department of Neurology, Haukeland University Hospital, Bergen, Norway
18
19

20
21 * Corresponding author

22 haln@haukeland.no
23

24 Department of Neurology
25

26 Haukeland University Hospital
27

28 Jonas Liesgt 65
29

30 5021 Bergen
31

32 Norway
33

34 Telephone: +4755975045
35

36 Fax: +4755975699
37
38
39
40
41
42

43 Key words: chronic fatigue syndrome, mononucleosis, prognosis, employment
44

45 Word count: 3234
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective - To examine the effect of early clinical and demographic factors on occupational outcome, return to work or awarded permanent disability pension in young patients with chronic fatigue syndrome (CFS)..

Design - Longitudinal cohort study.

Intervention - A written self-management program including a description of active coping strategies for daily life was provided.

Setting, participants - Patients with CFS after mononucleosis were evaluated at Department of Neurology, Haukeland University Hospital during 1996-2006 (Contact1). In 2009 self-report questionnaires were sent to all patients (Contact2).

Primary and secondary outcome measures - Primary measure was employment status on Contact2. Secondary measures included clinical symptoms, and Fatigue Severity Scale (FSS) scores on both contacts, and Work and Social Adjustment Scale (WSAS) on Contact2.

Results - Of 111 patients at Contact1, 92 (83%) patients returned the questionnaire at Contact2. Mean disease duration at Contact1 was 4.7 years and at Contact2 11.4 years. At Contact1, 9 (10%) were part or full time employed. At Contact2, 49 (55%) were part or full time employed. Logical regression analysis showed that $FSS \geq 5$ at Contact2 was associated with depression, arthralgia, and long disease duration (all at Contact1).

Conclusion - About half of younger CFS patients with long-term incapacity for work experienced marked improvement including full or part-time employment showing better outcomes than expected. Risk factors for transition to permanent disability were depression, arthralgia and disease duration.

1
2
3 **Article summary**
4

5
6 *Strengths and limitations of this study*
7

8
9 Two strengths of the study are very long prospective follow up period and focus on
10
11 employment.
12

13
14 A limitation is that patients were recruited from a tertiary center.
15

16
17 Long-term prognosis for young patients with CFS after mononucleosis is favorable for a large
18
19 subgroup.
20

21
22 More than half of the patients with long-term incapacity for work are re-employed after mean
23
24 disease duration of 11.4 years.
25

26
27 Factors associated with poor long-term prognosis include depression, arthralgia and disease
28
29 duration.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic fatigue syndrome (CFS) is a complex incapacitating illness of unknown cause.^{1,2} CFS is characterized by persistent/recurrent post-exertional fatigue of at least 6 months' duration accompanied by at least four of eight specific symptoms including impaired short-term memory or concentration, severe enough to cause substantial reduction in previous levels of occupational, educational, social or personal activities; headache of a new type, pattern or severity; muscle pain; multi-joint pain without swelling or redness; sore throat; tender cervical or axillary lymph nodes; unrefreshing sleep; post-exertional malaise, an exaggerated fatigue response to previous well tolerated activities.^{1,3}

Recent population-based epidemiologic studies using the 1994 Centers for Disease Control case definition have reported the overall CFS prevalence to be 71 and 190 per 100,000 persons, respectively in Olmsted County, Minnesota and three regions of England.^{4,5} CFS occurs in individuals during peak years of employment (age 20-50) with female preponderance. Rates of unemployment are high.⁶ Work-related physical and cognitive impairments are demonstrable with prolongation and recurrence of sickness absence episodes that can be the first step in a process leading to prolonged medical leave and awarded disability benefits.⁷

Knowledge about the natural history and prognostic factors in CFS is important as it relates to several aspects of the illness; information and advice to newly diagnosed patients, planning of health care and rehabilitation strategies that focus on volitional and social aspects of re-employment.⁸ Being unable to fulfill valued and expected social functions, including employment, can have a dramatic impact

1
2
3 on their self-concept with need to re-evaluate life goals, as well as increased stress
4
5 on the part of caregivers.⁹
6
7

8 Few patient-based longitudinal studies have examined employment outcomes as
9
10 measure of prognosis in the case of CFS.^{10 11} The objectives of this prospective
11
12 study of a cohort of younger CFS patients without systematic intervention were
13
14 to document the natural course of illness and to identify predictors of work
15
16 cessation or re-entry into work force. Only patients with CFS subsequent to
17
18 mononucleosis were included in this study. The patients were given a written self-
19
20 management program including a description of active coping strategies for daily
21
22 life. A small proportion of people that develop infectious mononucleosis remain
23
24 sick with CFS.¹² A recent follow-up study of the course and outcome of CFS in
25
26 adolescents after mononucleosis showed that most individuals recover; however
27
28 13 of 301 adolescents, 4% , all female, met the criteria of CFS after 2 years.¹³
29
30
31
32

33 We hypothesized that baseline clinical presentations such as cognitive problems,
34
35 pain and depression at the time of referral in addition to severe fatigue and long
36
37 illness duration prior to the evaluation predict long-term functional disability
38
39 including unemployment and awarded disability benefits.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Material and methods

Patients

The 111 young patients, mean age 23 year, participating in this study were part of a larger cohort of 873 consecutive patients referred from all over Norway to a specialist chronic fatigue clinic at the Department of Neurology, Haukeland University Hospital during 1996-2006, published previously.¹⁴ All patients were interviewed and examined by a specialist physician, HIN, who confirmed the diagnosis of CSF meeting the Centers for Disease Control and Prevention (CDC) case definition.¹

All received information about the illness to provide the patients with a rationale and structured meaning for their illness experience. A written self-management program included a description of active coping strategies for daily life; graded activity planning and consistent rest periods to minimize fluctuations in fatigue and symptoms as important principles for rehabilitation and occupational interventions in the local social setting.¹⁵ The family doctor and the local National Sickness Benefit Scheme office (NAV) received a specialist report on the medical history and investigations, the clinical characteristics and disability.¹⁶

The Norwegian Social and Insurance Scheme accepted CFS as a medico-legal diagnosis entitled to sickness and disability benefits to compensate for income loss in 1995.¹⁷ To receive long-term sickness absence (SA) benefits a sickness certificate has to be issued by a physician describing the cause of absence and plans for treatment. A disability pension (DP) is given to individuals aged 18 to 66 to compensate for permanent work-life exit before scheduled age retirement after relevant treatment or vocational rehabilitation.¹⁸

1
2
3 Primary outcome measures at long-term follow-up were employment: return to
4 part- or full-time work, or transition to ill-health retirement and receipt of
5 permanent disability pension. Secondary outcomes were self-rated scales of
6 clinical change, fatigue, disability and CFS somatic symptoms.
7
8
9

10
11
12 *Contact 1. Initial baseline evaluation*
13

14
15 All patients completed a questionnaire at referral that included questions about the
16 mode of clinical onset; the time from the triggering infection to debilitating
17 fatigue defined as acute, taking days or weeks, or gradual, taking months, and
18 duration of the illness. Questions about presenting symptoms comprised the
19 presence or not of concentration or memory problems, throat pain, enlarged or
20 tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia, weight
21 change, frequent micturition, photophobia, slurred vision, dizziness, tinnitus, sleep
22 disturbances, depression, unstable mood, palpitations, fever, increased sweating
23 and headache. Post-exertional malaise (PEM)¹⁹ was assessed with the following
24 question: do physical activity influence fatigue; improving, no effect, some
25 worsening, much worsening?
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40
41 Fatigue was self-rated by the Fatigue Severity Scale (FSS).²⁰ This is a 9- item
42 questionnaire that assesses the effect of fatigue on daily living. Each item is a
43 statement on fatigue that the subject rates from 1, “completely disagree” to 7,
44 “completely agree”. Examples of the items in the questionnaire are: “My
45 motivation is lower when I am fatigued”, “Exercise brings on my fatigue” and “I
46 am easily fatigued”. The average score of the 9 items represents the FSS score
47 (minimum score is 1 and maximum score is 7). Patients with a mean FSS score >5
48 are defined as having severe fatigue.²¹
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Employment status was noted as employed full-time, part-time or unemployed.

4
5 Sick leave from work or study, long term SA benefits and DP were registered.

6
7 Employment or studies at the time of the triggering mononucleosis were
8
9 registered.

10
11
12 *Contact2. Follow-up during 2009*

13
14
15 Self-report questionnaires were sent to the patients in 2009 on average 6.5 years
16
17 after Contact 1. A clinical symptom questionnaire included questions as to
18
19 presence or not of problems with concentration and memory, throat pain, enlarged
20
21 or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia, nausea,
22
23 weight change, frequent micturition, photophobia, slurred vision, dizziness,
24
25 tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever,
26
27 increased sweating and headache.

28
29
30 The Work and Social Adjustment Scale (WSAS) was used to measure disability.
31
32 It is a five-item scale that assesses an individual's ability to perform everyday
33
34 activities including work, home management, family and relationship interaction,
35
36 and social and private leisure activities. Each of the five items was rated on a 9-
37
38 point scale ranging from 0 (not at all a problem) to 8 (severely impaired) so that
39
40 the total scores range between 0 and 40.²² The psychometric properties have been
41
42 validated in large CFS patient cohorts confirming that WSAS is a reliable
43
44 assessment tool for disability. High scores correlate with severe fatigue and poor
45
46 physical fitness.¹⁶

47
48
49 Fatigue was self-rated by the FFS scale. Based on change in FSS score change
50
51 from baseline, Contact 1, the disease course was defined; FSS change <-1 was
52
53 defined as worsening course; FSS change \geq -1 and \leq 1 was defined as no change;
54
55
56
57
58
59
60

1
2
3 FSS change >1 was defined as improvement. Self-rated global clinical outcome
4
5 was scored as worsening, stable, improvement and recovered. Employment status,
6
7 sickness and disability benefits were recorded providing objective evidence of
8
9 disability. Outcome questions included the patients' rating of overall worsening or
10
11 improvement, and employment or disability benefit status.
12

13 14 15 *Statistics*

16
17 Student's t-test, chi-square test, Fisher's exact test, and pair-wise correlation test
18
19 were performed when appropriate. The FFS score was dichotomized and FFS
20
21 score ≥ 5 defined as pathological fatigue. Logistic regression analyses were
22
23 performed with dichotomized FFS score as dependent variable. STATA 12.0 was
24
25 used for analyses.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

In total, 111 patients participated in the baseline evaluation (Contact 1). Postal questionnaires were completed and returned by 92 (83%) of these patients on follow-up; 30 (33%) males and 62 (67%) females (Contact 2). The mean age of the patients at the onset of CFS was 23.7 years (SD 7.3). Mean duration of CFS at the time of Contact1 was 4.7 years (SD 4.0), (median 3.2 years, inter-quartile range (IQR) 1.9 – 6.4). Mean time from debut of CFS to Contact2 was 11.4 years (SD 4.3) (median 10.3 years, IQR 8.5 – 13.5) (range 4.7 – 23.8). At the time of mononucleosis 43 (47%) were employed at work and 48 (52%) were students.

At Contact 1 nine (10.2%) patients remained employed (1 full time and 8 part time), 12 patients (13.5%) were students and 70 patients (81%) were neither employed nor studying. One patient (1%) was receiving partial DP and 7 patients (8%) were receiving full DP. Fourteen (15%) patients received partial long-term sickness absence benefits, and 62 (67%) patients received full long-term sickness absence benefits.

At Contact 2 twenty-four (27%) were fully employed, 25 (28%) were employed part-time and 40 (45%) were unemployed. One patient (1%) was student. Fifteen patients (17%) were awarded partial DP and 39 (44%) received full DP for the reduced working capacity. Six patients (7%) got partial sickness absence benefits and 3 patients (3%) full sickness absence benefits. One (1%) unemployed patient was part time student. Five (5%) patients were employed at both Contact 1 and Contact 2.

Logistic regression analyses showed that being employed on Contact 2 was associated with lack of arthralgia (OR=.3, P=.028) and reporting improvement

1
2
3 (OR=1.8, P=.062) on Contact1. Another regression analyses showed that being
4
5 employed was associated with low FSS score on Contact 2 (OR=.53, P<.001),
6
7 lack of arthralgia (OR=.40, P=.041), and lack of concentration problems (OR=.32,
8
9 P=.064), but none of the other symptoms reported at Contact 2.

10
11
12 There was no correlation between FSS score on Contact 2 and degree of post-
13
14 exertional malaise on Contact1 (P=.57). There was no correlation between mode
15
16 of onset of fatigue after mononucleosis (acute or taking months) and FSS score on
17
18 Contact 2 (P=.61). Neither was there any correlation between employment status
19
20 on Contact 2 and degree of post-exertional malaise on Contact 1 (P=.91) nor mode
21
22 of onset (P=.59)
23
24

25
26 Based on FSS change from Contact 1 to Contact 2 38 (44%) (FSS
27
28 improvement>1) improved, 42 (48%) (FSS change ≤ 1 and ≥ -1) did not change
29
30 and 7 (8%) worsened (FSS change <-1). Based on self-assessment 10 (12%) had
31
32 worsened, 14 (17%) were stable, 47 (57%) had improved and 11 (13%) had
33
34 recovered on Contact 2.
35
36

37
38 The correlation between self-rated clinical change between Contact1 and Contact2
39
40 and employment status at Contact 2 was $r = .54$ (P<.001). The correlation between
41
42 change in FSS from Contact 1 to Contact 2 and employment status was $r = .30$
43
44 (P=.01). The correlation between FSS score on Contact 2 and employment was
45
46 $r = .51$ (P<.001). The correlation between WSAS score and employment was $r = .74$
47
48 (P<.001). The correlation between WSAS score and FSS score at Contact 2 was
49
50 $r = .81$ (P<.001).
51
52
53

54
55 Clinical characteristics based on evaluation at Contact1 and Contact2 are shown in
56
57 Table 1. Mean FSS score dropped from 6.4 to 5.0 (P<.001). CFS symptom
58
59
60

1
2
3 pattern showed significant less frequencies of concentration and memory
4
5 problems, headache, myalgia, sleep disturbances (all $P < .005$), but no changes as
6
7 to depression and arthralgia. A comparison between patients with $FSS \geq 5$ versus
8
9 $FSS < 5$ at Contact2 is shown in Table 2 and 3. Logistic regression showed that
10
11 $FSS \geq 5$ (versus $FSS < 5$) on Contact2 was associated with the following variables
12
13 registered at Contact 1: arthralgia (OR= 3.1, $P = .026$), depression (OR=4.0,
14
15 $P = .029$), duration of disease (OR=1.2, $P = .043$), and male sex (OR=2.6, $P = .087$).
16
17 Linear regression analysis with FSS score at Contact2 as dependent variable
18
19 showed that arthralgia, depression and level of education accounted for 22% of
20
21 the variation of the FSS score (R-squared = .22). Disability was evaluated
22
23 according to the WSAS, and table 4 shows linear regression with WSAS score as
24
25 dependent variable and variables registered at Contact 1. WSAS score was
26
27 significantly associated with depression, arthralgia, clinical change, psychic stress
28
29 and level of education (R-squared=.28)
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Our main finding was that about half of the patients improved during the study period and were fully or partly employed at the final follow-up. This shows that the occupational outcome is favorable in a considerable fraction of younger CFS patients after on average 5 years sickness absence from work. However, the transition to partly (15 patients) or full (39 patients) permanent disability pension shows that a substantial proportion develop chronic incapacity for work with severe negative consequences both for the individual and for the wider society and economy.

Few studies have examined employment status over time using operational criteria for CFS and standardized measurements of disability and functioning to provide information about the numbers of patients who were functionally impaired and unable to work.¹¹ To our knowledge this study is the longest follow-up study of CFS that has been published. Another long-term follow-up study included 33 patients, mean age 43 year, who answered identical questionnaires at diagnosis, after 4 years illness duration, and 5 years later. Work disability was very high at baseline (77%) and increased to 91 % at 5-year follow-up.²³ A prospective study including 246 patients found little improvement in occupational status after a follow-up period of 18 months. Before onset of complaints 141 (57%) patients worked. At initial assessment 69 (28%) worked and 105 (43%) were on sick leave or receiving disability benefits. At follow-up 71 patients (29%) worked and 103 (42%) were on sick leave. Self-reported improvement was indicated by 50 patients (20%), and 49 (20%) reported worsening of complaints.²⁴ Another study reported the outcome for 35 CFS patients, mean age 35 years

1
2
3 evaluated 42 months after the initial visit. Higher unemployment rates were found
4
5 at follow-up; 77% of patients versus 68% at baseline assessment.²⁵
6
7

8 A few longitudinal studies have reported employment at baseline and follow-up
9
10 after intervention. A long-term study of cognitive behavior therapy versus
11
12 relaxation therapy evaluated outcome at 5-year follow-up. A total of 68% of the
13
14 25 patients who received cognitive therapy rated themselves as improved
15
16 compared to 36% of the 28 patients who received relaxation therapy. Similar
17
18 proportions of patients were employed (56% versus 39%) but the patients in the
19
20 cognitive behavior group worked more hours per week (36 versus 24).²⁶ In
21
22 another study, cognitive behavior therapy was compared with a guided support
23
24 group and a natural course group at baseline and 14 months follow-up. Self-rated
25
26 improvement was recorded in 28/58 (50%) in the cognitive therapy group versus
27
28 24/76 (32%) in the natural course group. However, no treatment effect of
29
30 cognitive behavior therapy as compared to natural course was found on work
31
32 rehabilitation, only hours working in a job were measured.²⁷
33
34
35
36
37

38 A randomized controlled trial of patient education to encourage graded exercise
39
40 resulted in substantial self-reported improvement in physical and occupational
41
42 functioning compared with standard medical care. The receipt of sickness benefit
43
44 at the start of treatment was associated with poor outcome.²⁸ Occupational
45
46 therapy with a lifestyle management program was offered to 74 patients after
47
48 median illness duration of 5 years. At follow-up 18 months later 31 (42%) of the
49
50 patients had returned to new employment, voluntary work or training.²⁹
51
52
53

54 A comprehensive review of the literature on the natural course of CFS shows
55
56 that the illness runs a chronic course in many sufferers and that less than 10% of
57
58
59
60

1
2
3 subjects return to pre-morbid levels of functioning.³⁰ A substantial improvement
4
5 has, however, been observed in children. A recent study describes variation in
6
7 the CFS clinical phenotype in a group of younger patients as compared to those
8
9 older than 50.³¹ In addition to the observed generally positive outcome for young
10
11 people that study shows that CFS is a heterogeneous condition of complex and
12
13 multifactorial etiology.^{6,32} Return to work after long-time sickness absence is a
14
15 complex process influenced by the severity of the disorder, personal factors,
16
17 work-related factors and the compensation system.
18
19

20
21 We found that all patients who were unemployed at the initial examination
22
23 received sickness or disability benefits. Norway has been criticized for high
24
25 disability payments which may undermine motivation for individuals to stay in
26
27 work.³³ A poor response to treatment for CFS was predicted by being in receipt of
28
29 sickness benefits in a patient education study.²⁸ In contrast, this study shows that
30
31 long-term compensations to secure the socio-economic position does not inhibit
32
33 return to work, but are probably essential contributors to the high proportion
34
35 becoming employed at final follow-up. In addition to the financial support the
36
37 contact with the social security system initiate rehabilitation activities directed
38
39 towards obtaining new work when unemployed.¹⁸
40
41
42
43

44
45 It is important to disclose predictors for long-term outcome as this may suggest
46
47 targets for management. We found that arthralgia at the first contact
48
49 independently predicted poor long-term prognosis as evaluated by employment,
50
51 FSS and WSAS scores. Arthralgia is a prominent and serious somatic symptom in
52
53 the majority of CFS patients.⁴ One may speculate that some patients with
54
55 arthralgia have underlying atypical chronic rheumatic disease which has not been
56
57
58
59
60

1
2
3 diagnosed. This suggests that CFS patients with arthralgia may need repeated
4
5 evaluation as to possible rheumatic disease.
6

7
8 We found that depression at the first contact tended to predict poor prognosis both
9
10 as to FSS and WSAS scores, but not employment. Depression is an exclusion
11
12 criterion of CFS, but many patients develop co-morbid depression reactive to the
13
14 chronic illness that may contribute to a poorer prognosis due to reduced illness
15
16 coping. Clinicians need training to be able to diagnose co-morbid psychiatric
17
18 disorders , particularly depression in order to offer appropriate treatment.³⁵ In
19
20 contrast to our findings another study comprising 177 patients did not find any
21
22 association between depression and final outcome.³⁶
23
24

25
26 We found that FSS score at the second contact was associated with duration of
27
28 illness disease at the first contact. This is compatible to the findings in a study of
29
30 natural course in CFS. Patients with a relative short duration of complaints had a
31
32 more favorable outcome³⁷. Most symptoms were reported significantly less
33
34 frequent on the second contact compared to the first contact. However, there was
35
36 no significant change as to depression, arthralgia or tender lymph nodes.
37
38

39
40 As shown above reviews on predictors of prognosis show conflicting results.¹¹
41
42 This is probably due to major differences between studies. Important differences
43
44 include varying number of patients, severity of disease and length of follow-up.
45
46 To compare studies at the very least CDC criteria should be used as well as FSS
47
48 scores and data on occupational status.
49
50

51
52 Two strengths of the present study are the long-follow up period and the relatively
53
54 high response rate as to the return of the postal questionnaire including details
55
56 about occupational status. Another of the strengths is that our patients were
57
58
59
60

1
2
3 evaluated at two different occasions with a long interval between including
4
5 information on occupational status on both occasions. This allowed us to predict
6
7 final outcome based on factors known at the first follow-up. Most long-term
8
9 follow-up studies of CFS have evaluated outcome based on factors known at the
10
11 final follow-up. One limitation of the study is that the patients were recruited
12
13 from a tertiary center and the patient cohort may represent some selection bias.
14
15 Whether the written self-management program contributed to better outcome than
16
17 expected is possible. This should be addressed in controlled studies in the future.
18
19
20
21 In conclusion, about half of younger CFS patients with long-term incapacity for
22
23 work got marked improvement including full or part-time employment. Self-
24
25 management strategies, long-term sickness absence benefits providing a stable
26
27 financial support, in addition to occupational interventions aimed at return to work
28
29 were likely contributors to the generally positive, prolonged outcome. Risk factors
30
31 for transition to permanent disability pension were depression, arthralgia and
32
33 disease duration.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Contributor statement:*
4

5
6 Morten Nyland: Data collection and manuscript preparation
7

8
9 Halvor Naess: Manuscript preparation and performing of analyses
10

11
12 Jon S Birkeland: Data collection and manuscript preparation
13

14
15 Harald Nyland: Data collection and manuscript preparation
16

17
18
19
20
21 Acknowledgements: none
22

23
24 Competing interests: none
25

26
27 Funding: none
28

29
30 The study was approved by the local ethics committee.
31

32
33 Data sharing is available by emailing Halvor Naess haln@haukeland.no
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med* 1994;121(12):953-9.
2. Salit IE. Precipitating factors for the chronic fatigue syndrome. *J Psychiatr Res* 1997;31(1):59-65.
3. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, et al. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. *BMC health services research* 2003;3(1):25.
4. Vincent A, Brimmer DJ, Whipple MO, Jones JF, Boneva R, Lahr BD, et al. Prevalence, incidence, and classification of chronic fatigue syndrome in Olmsted County, Minnesota, as estimated using the Rochester Epidemiology Project. *Mayo Clin Proc* 2012;87(12):1145-52.
5. Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, et al. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. *BMC medicine* 2011;9:91.
6. Wilson A, Hickie I, Hadzi-Pavlovic D, Wakefield D, Parker G, Straus SE, et al. What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. *The Australian and New Zealand journal of psychiatry* 2001;35(4):520-7.
7. Marmot M, Feeney A, Shipley M, North F, Syme SL. Sickness absence as a measure of health status and functioning: from the UK Whitehall II study. *J Epidemiol Community Health* 1995;49(2):124-30.
8. Taylor RR, Kielhofner GW. Work-related impairment and employment-focused rehabilitation options for individuals with chronic fatigue syndrome: A review. *Journal of Mental Health* 2005;14(3):253-67.
9. Ware NC. Sociosomatics and illness in chronic fatigue syndrome. *Psychosomatic medicine* 1998;60(4):394-401.
10. Ross SD, Estok RP, Frame D, Stone LR, Ludensky V, Levine CB. Disability and chronic fatigue syndrome: a focus on function. *Arch Intern Med* 2004;164(10):1098-107.
11. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. *Occupational medicine* 2005;55(1):20-31.
12. White PD, Thomas JM, Amess J, Crawford DH, Grover SA, Kangro HO, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. *The British journal of psychiatry : the journal of mental science* 1998;173:475-81.
13. Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome after infectious mononucleosis in adolescents. *Pediatrics* 2009;124(1):189-93.
14. Naess H, Sundal E, Myhr KM, Nyland HI. Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. *In vivo* 2010;24(2):185-8.
15. Nijs J, Paul L, Wallman K. Chronic fatigue syndrome: an approach combining self-management with graded exercise to avoid exacerbations. *J Rehabil Med* 2008;40(4):241-7.
16. Cella M, Sharpe M, Chalder T. Measuring disability in patients with chronic fatigue syndrome: reliability and validity of the Work and Social Adjustment Scale. *J Psychosom Res* 2011;71(3):124-8.
17. Haukenes G, Aarli JA. [Postviral fatigue syndrome]. *Tidsskr Nor Laegeforen* 1995;115(24):3017-22.
18. Gjesdal S, Bratberg E. Diagnosis and duration of sickness absence as predictors for disability pension: results from a three-year, multi-register based* and prospective study. *Scandinavian journal of public health* 2003;31(4):246-54.
19. Van Ness J, Stevent S, Bateman L, Stiles T, Snell C. Postexertional Malaise in Women with Chronic Fatigue Syndrome. *Journal of Women's Health* 2010;19(2):239-44.
20. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;46(10):1121-3.

21. Lerdal A, Wahl A, Rustoen T, Hanestad BR, Moum T. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. *Scandinavian journal of public health* 2005;33(2):123-30.
22. Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. *The British journal of psychiatry : the journal of mental science* 2002;180:461-4.
23. Andersen MM, Permin H, Albrecht F. Illness and disability in Danish Chronic Fatigue Syndrome patients at diagnosis and 5-year follow-up. *J Psychosom Res* 2004;56(2):217-29.
24. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Prognosis in chronic fatigue syndrome: a prospective study on the natural course. *J Neurol Neurosurg Psychiatry* 1996;60(5):489-94.
25. Tiersky LA, DeLuca J, Hill N, Dhar SK, Johnson SK, Lange G, et al. Longitudinal assessment of neuropsychological functioning, psychiatric status, functional disability and employment status in chronic fatigue syndrome. *Applied neuropsychology* 2001;8(1):41-50.
26. Deale A, Husain K, Chalder T, Wessely S. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. *The American journal of psychiatry* 2001;158(12):2038-42.
27. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. *Lancet* 2001;357(9259):841-7.
28. Bentall RP, Powell P, Nye FJ, Edwards RH. Predictors of response to treatment for chronic fatigue syndrome. *The British journal of psychiatry : the journal of mental science* 2002;181:248-52.
29. McDermott C, Richards SC, Ankers s, Selby M, Harmer J, Moran CJ. An evaluation of a chronic fatigue lifestyle management programme focusing on the outcome of return to work or training. *British Journal of Occupational Therapy* 2004;67(6):269-73.
30. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. *Qjm* 1997;90(3):223-33.
31. Lewis I, Pairman J, Spickett G, Newton JL. Is chronic fatigue syndrome in older patients a different disease? -- a clinical cohort study. *European journal of clinical investigation* 2013;43(3):302-8.
32. Cho HJ, Skowera A, Cleare A, Wessely S. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. *Current opinion in psychiatry* 2006;19(1):67-73.
33. Markussen S, Roed K, Rogeberg OJ, Gaure S. The anatomy of absenteeism. *Journal of health economics* 2011;30(2):277-92.
34. Akagi H, Klimes I, Bass C. Cognitive behavioral therapy for chronic fatigue syndrome in a general hospital--feasible and effective. *General hospital psychiatry* 2001;23(5):254-60.
35. Lawn T, Kumar P, Knight B, Sharpe M, White PD. Psychiatric misdiagnoses in patients with chronic fatigue syndrome. *JRSM short reports* 2010;1(4):28.
36. Pheley AM, Melby D, Schenck C, Mandel J, Peterson PK. Can we predict recovery in chronic fatigue syndrome? *Clinical & Health Affairs* 1999;82:52-56.
37. van der Werf SP, de Vree B, Alberts M, van der Meer JW, Bleijenberg G, Netherlands Fatigue Research Group N. Natural course and predicting self-reported improvement in patients with chronic fatigue syndrome with a relatively short illness duration. *J Psychosom Res* 2002;53(3):749-53.

Table 1 Symptoms on Contac1 and Contac2

	Contact1	Contact2	p
FSS score, mean (SD)	6.4 (.96)	5.0 (1.9)	<.001
Headache	61 (71)	47 (52)	.033
Myalgia	65 (72)	52 (58)	.042
Arthralgia	43 (48)	38 (42)	.45
Sleep disturbances	60 (66)	47 (52)	.048
Depression	30 (33)	25 (28)	.42
Concentration problems	83 (92)	58 (64)	<.001
Memory problems	72 (79)	51 (56)	<.001

FSS: Fatigue Severity Score

SD: Standard deviation

Table 2 FSS score >5 or <5 on second follow-up and symptoms on Contact1

	Number of patients	FSS<5	FSS>5	P
Males	30	9 (25)	21 (39)	.17
Females	60	27 (75)	33 (61)	
Age debut of CFS		23.8 (7.9)	24.1 (7.0)	.85
Age (second control)		33.6 (7.9)	35.8 (6.9)	.17
<i>First control</i>				
Age (first control)		26.8 (7.5)	29.3 (7.0)	.11
FSS score (mean)		6.3 (1.2)	6.4 (.8)	.63
Duration of CFS (yearssum , mean)		3.3 (2.4)	5.6 (4.5)	.006
Arthralgia	89	11 (33)	32 (59)	.010
Myalgia	89	24 (69)	40 (74)	.57
Headache	89	25 (71)	38 (70)	.92
Sleeping disturbances	90	23 (64)	36 (67)	.79
Depression	89	8 (23)	22 (41)	.081
Concentration problems	89	32 (91)	50 (93)	.84
Memory problems	90	30 (83)	41 (76)	.40
Clinical change prior to first control	71			.06
Improvement		16 (55)	12 (29)	
No change		4 (14)	13 (31)	
Worsening		9 (31)	17 (40)	

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

Table 3 FSS score >5 or <5 on second follow-up and symptoms on Contact2

	Number of patients	FSS<5	FSS>5	P
Age (second control)	92	33.6 (7.9)	35.8 (6.9)	.17
Duration of CFS (years, mean)	90	10.1 (3.1)	12.1 (4.7)	.028
Arthralgia	90	7 (19)	31 (57)	<.001
Myalgia	90	11 (31)	41 (76)	<.001
Headache	90	11 (31)	35 (65)	.001
Sleeping disturbances	90	9 (25)	37 (69)	<.001
Depression	90	4 (11)	20 (37)	.006
Concentration problems	90	14 (39)	43 (80)	<.001
Memory problems	90	12 (33)	38 (70)	.001

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

**Table 4 Linear regression with WSAS
as dependent variable and variable
registered at Contact1**

	Beta	P-value
Sex	<.001	1.0
Age	.16	.17
Depression	.27	.026
Arthralgia	.25	.041
Clinical change	-.26	.031
Psychic stress	-.28	.025
Education	-.27	.21

WSAS: Work and Social Adjustment Scale

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-9
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	10
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	10-11 10-11
Outcome data	15*	Report numbers of outcome events or summary measures over time	10-12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Longitudinal follow up of employment status in patients with chronic fatigue syndrome after mononucleosis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005798.R1
Article Type:	Research
Date Submitted by the Author:	02-Oct-2014
Complete List of Authors:	Nyland, Morten; Haukeland Universiyt Hospital, Neurology Naess, Halvor; Haukeland University Hospital, Neurology Birkeland, Jon; Haukeland Universiyt Hospital, Neurology Nyland, Harald; Haukeland Universiyt Hospital, Neurology
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Health economics, Infectious diseases
Keywords:	Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Infectious disease/HIV < NEUROLOGY, OCCUPATIONAL & INDUSTRIAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 Longitudinal follow up of employment status in patients with chronic
4 fatigue syndrome after mononucleosis
5
6
7
8

9 **Morten Nyland¹ cand. polit., Halvor Naess^{12*} MD, Jon Steinar Birkeland² MD, Harald**
10 **Nyland¹ MD**
11

12
13
14
15 ¹ Institute of clinical medicine, University of Bergen, Bergen, Norway

16
17 ² Department of Neurology, Haukeland University Hospital, Bergen, Norway
18
19

20
21 * Corresponding author

22 haln@haukeland.no
23

24 Department of Neurology
25

26 Haukeland University Hospital
27

28 Jonas Liesgt 65
29

30 5021 Bergen
31

32 Norway
33

34 Telephone: +4755975045
35

36 Fax: +4755975699
37
38
39
40
41
42

43 Key words: chronic fatigue syndrome, mononucleosis, prognosis, employment
44

45 Word count: 3410
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective - To examine the effect of early clinical and demographic factors on occupational outcome, return to work or awarded permanent disability pension in young patients with chronic fatigue syndrome (CFS).

Design - Longitudinal cohort study.

Intervention - A written self-management program including a description of active coping strategies for daily life was provided.

Setting, participants - Patients with CFS after mononucleosis were evaluated at Department of Neurology, Haukeland University Hospital during 1996-2006 (Contact 1). In 2009 self-report questionnaires were sent to all patients (Contact 2).

Primary and secondary outcome measures - Primary measure was employment status at Contact 2. Secondary measures included clinical symptoms, and Fatigue Severity Scale (FSS) scores on both contacts, and Work and Social Adjustment Scale (WSAS) at Contact 2.

Results - Of 111 patients at Contact 1, 92 (83%) patients returned the questionnaire at Contact 2. Mean disease duration at Contact 1 was 4.7 years and at Contact 2 11.4 years. At Contact 1, 9 (10%) were part or full time employed. At Contact 2, 49 (55%) were part or full time employed. Logical regression analysis showed that $FSS \geq 5$ at Contact 2 was associated with depression, arthralgia, and long disease duration (all at Contact 1).

Conclusion - About half of younger CFS patients with long-term incapacity for work experienced marked improvement including full or part-time employment showing better outcomes than expected. Risk factors for transition to permanent disability were depression, arthralgia and disease duration.

1
2
3 **Article summary**
4

5
6 *Strengths and limitations of this study*
7

8
9 Two strengths of the study are very long prospective follow up period and focus on
10 employment.
11

12
13 A limitation is that patients were recruited from a tertiary center.
14

15
16
17 Long-term prognosis for young patients with CFS after mononucleosis is favorable for a large
18 subgroup.
19

20
21
22 More than half of the patients with long-term incapacity for work are re-employed after mean
23 disease duration of 11.4 years.
24

25
26
27 Factors associated with poor long-term prognosis include depression, arthralgia and disease
28 duration.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic fatigue syndrome (CFS) is a complex incapacitating illness of unknown cause.^{1,2} CFS is characterized by persistent/recurrent post-exertional fatigue of at least 6 months' duration accompanied by at least four of eight specific symptoms including impaired short-term memory or concentration, severe enough to cause substantial reduction in previous levels of occupational, educational, social or personal activities; headache of a new type, pattern or severity; muscle pain; multi-joint pain without swelling or redness; sore throat; tender cervical or axillary lymph nodes; unrefreshing sleep; post-exertional malaise, an exaggerated fatigue response to previous well tolerated activities.^{1,3} The clinical condition has received increased attention in the past two decades from medical, psychological and social security/insurance communities. The term ``Chronic Fatigue Syndrome`` was coined in 1988 by the US Centres for Disease Control (CDC) and the present case definition was developed by a joint CDC/National Institute of Health (NIH) international working group.¹ The excessive fatigue and fatigueability with disproportionately prolonged recovery after exercise or activity differentiate CFS from other fatigue conditions.

Recent population-based epidemiologic studies using the 1994 Centers for Disease Control case definition have reported the overall CFS prevalence to be 71 and 190 per 100,000 persons, respectively in Olmsted County, Minnesota and three regions of England.^{4,5} CFS occurs in individuals during peak years of employment (age 20-50) with female preponderance. Rates of unemployment are high.⁶ Work-related physical and cognitive impairments are demonstrable with prolongation and recurrence of sickness absence episodes that can be the first step in a process leading to prolonged medical leave and awarded disability benefits.⁷

1
2
3 Knowledge about the natural history and prognostic factors in CFS is important as
4 it relates to several aspects of the illness; information and advice to newly
5 diagnosed patients, planning of health care and rehabilitation strategies that focus
6 on volitional and social aspects of re-employment.⁸ Being unable to fulfill valued
7 and expected social functions, including employment, can have a dramatic impact
8 on their self-concept with need to re-evaluate life goals, as well as increased stress
9 on the part of caregivers.⁹

10
11 Few patient-based longitudinal studies have examined employment outcomes as
12 measure of prognosis in the case of CFS.^{10 11} The objectives of this prospective
13 study of a cohort of younger CFS patients without systematic intervention were
14 to document the natural course of illness and to identify predictors of work
15 cessation or re-entry into work force. Only patients with CFS subsequent to
16 mononucleosis were included in this study. The patients were given a written self-
17 management program including a description of active coping strategies for daily
18 life. A small proportion of people that develop infectious mononucleosis remain
19 sick with CFS.¹² A recent follow-up study of the course and outcome of CFS in
20 adolescents after mononucleosis showed that most individuals recover; however
21 13 of 301 adolescents, 4% , all female, met the criteria of CFS after 2 years.¹³

22
23 We hypothesized that baseline clinical presentations such as cognitive problems,
24 pain and depression at the time of referral in addition to severe fatigue and long
25 illness duration prior to the evaluation predict long-term functional disability
26 including unemployment and awarded disability benefits.

Material and methods

Patients

The 111 young patients, mean age 23 year, participating in this study were part of a larger cohort of 873 consecutive patients referred from all over Norway to a specialist chronic fatigue clinic at the Department of Neurology, Haukeland University Hospital during 1996-2006, published previously.¹⁴ All patients were interviewed and examined by a specialist physician, HIN, who confirmed the diagnosis of CSF meeting the Centers for Disease Control and Prevention (CDC) case definition.¹ The 111 patients constitute all patients diagnosed with CSF triggered by mononucleosis in the total cohort of 873 patients. The diagnosis of mononucleosis was based on the physician report following the patient to our clinic.

All received information about the illness to provide the patients with a rationale and structured meaning for their illness experience. A written self-management program included information about the illness to provide the patients with a rationale and structural meaning for their illness experience.¹⁵ Active coping strategies for daily life included graded activity planning; encouraging activity, but staying within their physical limitations with consistent rest periods to minimize fluctuations in fatigue and symptoms. To avoid occupational impairment and restore ability to work the importance to keep contact with the local health and rehabilitation services, and inform the employer was stressed. The family doctor and the local National Sickness Benefit Scheme office (NAV) received a specialist report on the medical history and investigations, the clinical characteristics and disability.¹⁶

1
2
3 The Norwegian Social and Insurance Scheme accepted CFS as a medico-legal
4 diagnosis entitled to sickness and disability benefits to compensate for income
5 loss in 1995.¹⁷ To receive long-term sickness absence (SA) benefits a sickness
6 certificate has to be issued by a physician describing the cause of absence and
7 plans for treatment. A disability pension (DP) is given to individuals aged 18 to
8 66 to compensate for permanent work-life exit before scheduled age retirement
9 after relevant treatment or vocational rehabilitation.¹⁸

10
11
12 Primary outcome measures at long-term follow-up were employment: return to
13 part- or full-time work, or transition to ill-health retirement and receipt of
14 permanent disability pension. Secondary outcomes were self-rated scales of
15 clinical change, fatigue, disability and CFS somatic symptoms.

16 17 18 19 20 21 22 23 24 25 26 27 28 29 *Contact 1. Initial baseline evaluation*

30
31
32 All patients completed a questionnaire at referral that included questions about the
33 mode of clinical onset (whether the fatigue appeared acutely or evolved gradually
34 over months and duration of the illness. Questions about presenting symptoms
35 comprised the presence or not of concentration or memory problems, throat pain,
36 enlarged or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia,
37 weight change, frequent micturition, photophobia, slurred vision, dizziness,
38 tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever,
39 increased sweating and headache. Post-exertional malaise (PEM)¹⁹ was assessed
40 with the following question: does physical activity influence fatigue; improving,
41 no effect, some worsening, much worsening?
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Fatigue was self-rated by the Fatigue Severity Scale (FSS).²⁰ This is a 9- item
56 questionnaire that assesses the effect of fatigue on daily living. Each item is a
57
58
59
60

1
2
3 statement on fatigue that the subject rates from 1, “completely disagree” to 7,
4
5 “completely agree”. Examples of the items in the questionnaire are: “My
6
7 motivation is lower when I am fatigued”, “Exercise brings on my fatigue” and “I
8
9 am easily fatigued”. The average score of the 9 items represents the FSS score
10
11 (minimum score is 1 and maximum score is 7). Patients with a mean FSS score >5
12
13 are defined as having severe fatigue.²¹
14
15

16
17 Employment status was noted as employed full-time, part-time or unemployed.

18
19 Sick leave from work or study, long term SA benefits and DP were registered.

20
21 Employment or studies at the time of the triggering mononucleosis were
22
23 registered.
24

25 26 27 *Contact 2. Follow-up during 2009*

28
29 Self-report questionnaires were sent to the patients in 2009 on average 6.5 years
30
31 after Contact 1. A clinical symptom questionnaire included questions as to
32
33 presence or not of problems with concentration and memory, throat pain, enlarged
34
35 or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia, nausea,
36
37 weight change, frequent micturition, photophobia, slurred vision, dizziness,
38
39 tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever,
40
41 increased sweating and headache.
42
43
44

45
46 The Work and Social Adjustment Scale (WSAS) was used to measure disability.

47
48 It is a five-item scale that assesses an individual's ability to perform everyday
49
50 activities including work, home management, family and relationship interaction,
51
52 and social and private leisure activities. Each of the five items was rated on a 9-
53
54 point scale ranging from 0 (not at all a problem) to 8 (severely impaired) so that
55
56 the total scores range between 0 and 40.²² The psychometric properties have been
57
58
59
60

1
2
3 validated in large CFS patient cohorts confirming that WSAS is a reliable
4
5 assessment tool for disability. High scores correlate with severe fatigue and poor
6
7 physical fitness.¹⁶
8
9

10
11 Fatigue was self-rated by the FFS scale. Based on change in FSS score change
12
13 from baseline, Contact 1, the disease course was defined; FSS change <-1 was
14
15 defined as worsening course; FSS change ≥ -1 and ≤ 1 was defined as no change;
16
17 FSS change >1 was defined as improvement. Self-rated global clinical outcome
18
19 was scored as worsening, stable, improvement and recovered. Employment status,
20
21 sickness and disability benefits were recorded providing objective evidence of
22
23 disability. Outcome questions included the patients' rating of overall worsening or
24
25 improvement, and employment or disability benefit status.
26
27

28 29 *Statistics*

30
31
32 Student's t-test, chi-square test, Fisher's exact test, and pair-wise correlation test
33
34 were performed when appropriate. The FFS score was dichotomized and FFS
35
36 score ≥ 5 defined as pathological fatigue. Stepwise backward logistic regression
37
38 analyses were performed with dichotomized FFS score at Contact 2 as dependent
39
40 variable. Stepwise backward linear regression analyses with FSS at Contact 2 and
41
42 WSAS as dependent variables were performed. STATA 12.0 was used for
43
44 analyses.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

In total, 111 patients participated in the baseline evaluation (Contact 1). Postal questionnaires were completed and returned by 92 (83%) of these patients on follow-up (Contact 2); 30 (33%) males and 62 (67%) females (Contact 2). The mean age of the patients at the onset of CFS was 23.7 years (SD 7.3). Mean duration of CFS at the time of Contact 1 was 4.7 years (SD 4.0), (median 3.2 years, inter-quartile range (IQR) 1.9 – 6.4). Mean time from debut of CFS to Contact 2 was 11.4 years (SD 4.3) (median 10.3 years, IQR 8.5 – 13.5) (range 4.7 – 23.8). At the time of mononucleosis 43 (47%) were employed at work and 48 (52%) were students.

Employment at Contact 1

At Contact 1 nine (10.2%) patients remained employed (1 full time and 8 part time), 12 patients (13.5%) were students and 70 patients (81%) were neither employed nor studying (missing data in one patient). One patient (1%) was receiving partial DP and 7 patients (8%) were receiving full DP. Fourteen (15%) patients received partial long-term sickness absence benefits, and 62 (67%) patients received full long-term sickness absence benefits (missing data in 8 patients).

Employment at Contact 2(primary measures)

At Contact 2 twenty-four (27%) were fully employed, 25 (28%) were employed part-time and 40 (45%) were unemployed (missing data in three patients). One patient (1%) was student. Fifteen patients (17%) were awarded partial DP and 39 (44%) received full DP for the reduced working capacity. Six patients (7%) got partial sickness absence benefits and 3 patients (3%) full sickness absence

1
2
3 benefits. One (1%) unemployed patient was part time student. Five (5%) patients
4
5 were employed at both Contact 1 and Contact 2. Figure 1 shows employment
6
7 status at Contact 1 and Contact 2.
8
9

10
11 Logistic regression analyses showed that being employed at Contact 2 was
12
13 associated with lack of arthralgia (OR=.3, P=.028) and reporting improvement
14
15 (OR=1.8, P=.062) at Contact 1. Another logistic regression analyses
16
17 showed that being employed at Contact 2 was associated with low FSS score at
18
19 Contact 2 (OR=.53, P<.001), lack of arthralgia (OR=.40, P=.041), and lack of
20
21 concentration problems (OR=.32, P=.064), but none of the other symptoms
22
23 reported at Contact 2.
24
25

26 27 *Secondary measures*

28
29
30 There was no correlation between FSS score at Contact 2 and degree of PEM at
31
32 Contact 1 (P=.57). There was no correlation between mode of onset of
33
34 fatigue after mononucleosis (acute or taking months) and FSS score at Contact 2
35
36 (P=.61). Neither was there any correlation between employment status at Contact
37
38 2 and degree of PEM at Contact 1 (P=.91) nor mode of onset (P=.59). There was
39
40 no correlation between degree of PEM at Contact 1 and FSS score at Contact 1
41
42 (P=.99).
43
44

45
46 Based on FSS change from Contact 1 to Contact 2, 38 (44%) (FSS
47
48 improvement >1) improved, 42 (48%) (FSS change ≤ 1 and ≥ -1) did not change
49
50 and 7 (8%) worsened (FSS change <-1). Based on self-assessment 10 (12%) had
51
52 worsened, 14 (17%) were stable, 47 (57%) had improved and 11 (13%) had
53
54 recovered at Contact 2.
55
56
57
58
59
60

1
2
3 The correlation between self-rated clinical change between Contact 1 and Contact
4
5 2 and employment status at Contact 2 was $r = .54$ ($P < .001$). The correlation
6
7 between change in FSS from Contact 1 to Contact 2 and employment status was
8
9 $r = .30$ ($P = .01$). The correlation between FSS score at Contact 2 and employment
10
11 was $r = .51$ ($P < .001$). The correlation between WSAS score and employment was
12
13 $r = .74$ ($P < .001$). The correlation between WSAS score and FSS score at Contact 2
14
15 was $r = .81$ ($P < .001$).
16
17

18
19 Clinical characteristics based on evaluation at Contact 1 and Contact 2 are shown
20
21 in Table 1. Mean FSS score dropped from 6.4 to 5.0 ($P < .001$). CFS symptom
22
23 pattern showed significant less frequencies of concentration and memory
24
25 problems, headache, myalgia, sleep disturbances at Contact 2 compared to
26
27 Contact 1 (all $P < .005$), but no changes as to depression and arthralgia. A
28
29 comparison between patients with $FSS \geq 5$ versus $FSS < 5$ at Contact 2 is shown in
30
31 Table 2 and 3.
32
33

34
35 Among 26 patients who reported improvement prior to Contact 1, 25 (96%)
36
37 reported further improvement at Contact 2, whereas among 38 patients who
38
39 reported worsening or no change at Contact 1, 23 (61%) reported improvement at
40
41 Contact 2 ($P = .001$).
42
43

44
45 Logistic regression showed that $FSS \geq 5$ (versus $FSS < 5$) at Contact 2 was
46
47 associated with the following variables registered at Contact 1: arthralgia (OR=
48
49 3.1, $P = .026$), depression (OR=4.0, $P = .029$), duration of disease (OR=1.2, $P = .043$),
50
51 and male sex (OR=2.6, $P = .087$). Linear regression analysis with FSS score at
52
53 Contact 2 as dependent variable showed that arthralgia, depression (both at
54
55
56
57
58
59
60

1
2
3 Contact 1) and level of education accounted for 22% of the variation of the FSS
4
5 score (R-squared = .22).
6
7

8 Disability was evaluated according to the WSAS, and table 4 shows linear
9
10 regression with WSAS score as dependent variable and variables registered at
11
12 Contact 1. WSAS score was significantly associated with depression, arthralgia,
13
14 clinical change, psychic stress and level of education (R-squared=.28)
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Our main finding was that about half of the patients improved during the study period and were fully or partly employed at the final follow-up. This shows that the occupational outcome is favorable in a considerable fraction of younger CFS patients after on average 5 years sickness absence from work. However, the transition to partly (15 patients) or full (39 patients) permanent disability pension shows that a substantial proportion develop chronic incapacity for work with severe negative consequences both for the individual and for the wider society and economy.

Few studies have examined employment status over time using operational criteria for CFS and standardized measurements of disability and functioning to provide information about the numbers of patients who were functionally impaired and unable to work.¹¹ To our knowledge this study is the longest follow-up study of CFS that has been published. Another long-term follow-up study included 33 patients, mean age 43 year, who answered identical questionnaires at diagnosis, after 4 years illness duration, and 5 years later. Work disability was very high at baseline (77%) and increased to 91 % at 5-year follow-up.²³ A prospective study including 246 patients found little improvement in occupational status after a follow-up period of 18 months. Before onset of complaints 141 (57%) patients worked. At initial assessment 69 (28%) worked and 105 (43%) were on sick leave or receiving disability benefits. At follow-up 71 patients (29%) worked and 103 (42%) were on sick leave. Self-reported improvement was indicated by 50 patients (20%), and 49 (20%) reported worsening of complaints.²⁴ Another study reported the outcome for 35 CFS patients, mean age 35 years

1
2
3 evaluated 42 months after the initial visit. Higher unemployment rates were found
4
5 at follow-up; 77% of patients versus 68% at baseline assessment.²⁵
6
7

8 A few longitudinal studies have reported employment at baseline and follow-up
9
10 after intervention. A long-term study of cognitive behavior therapy versus
11
12 relaxation therapy evaluated outcome at 5-year follow-up. A total of 68% of the
13
14 25 patients who received cognitive therapy rated themselves as improved
15
16 compared to 36% of the 28 patients who received relaxation therapy. Similar
17
18 proportions of patients were employed (56% versus 39%) but the patients in the
19
20 cognitive behavior group worked more hours per week (36 versus 24).²⁶ In
21
22 another study, cognitive behavior therapy was compared with a guided support
23
24 group and a natural course group at baseline and 14 months follow-up. Self-rated
25
26 improvement was recorded in 28/58 (50%) in the cognitive therapy group versus
27
28 24/76 (32%) in the natural course group. However, no treatment effect of
29
30 cognitive behavior therapy as compared to natural course was found on work
31
32 rehabilitation, only hours working in a job were measured.²⁷
33
34
35
36

37 A randomized controlled trial of patient education to encourage graded exercise
38
39 resulted in substantial self-reported improvement in physical and occupational
40
41 functioning compared with standard medical care. The receipt of sickness benefit
42
43 at the start of treatment was associated with poor outcome.²⁸ Occupational
44
45 therapy with a lifestyle management program was offered to 74 patients after
46
47 median illness duration of 5 years. At follow-up 18 months later 31 (42%) of the
48
49 patients had returned to new employment, voluntary work or training.²⁹
50
51
52

53 A comprehensive review of the literature on the natural course of CFS shows
54
55 that the illness runs a chronic course in many sufferers and that less than 10% of
56
57
58
59
60

1
2
3 subjects return to pre-morbid levels of functioning.³⁰ A substantial improvement
4 has, however, been observed in younger individuals. A recent study describes
5 variation in the CFS clinical phenotype in a group of younger patients as
6 compared to those older than 50.³¹ In addition to the observed generally positive
7 outcome for young people that study shows that CFS is a heterogeneous condition
8 of complex and multifactorial etiology.^{6,32} Return to work after long-time sickness
9 absence is a complex process influenced by the severity of the disorder, personal
10 factors, work-related factors and the compensation system.
11
12
13
14
15
16
17
18
19

20
21 We found that all patients who were unemployed at the initial examination
22 received sickness or disability benefits. Norway has been criticized for high
23 disability payments which may undermine motivation for individuals to stay in
24 work.³³ A poor response to treatment for CFS was predicted by being in receipt of
25 sickness benefits in a patient education study.²⁸ In contrast, this study shows that
26 long-term compensations to secure the socio-economic position does not inhibit
27 return to work, but may be essential contributors to the high proportion
28 becoming employed at final follow-up. In addition to the financial support the
29 contact with the social security system initiates rehabilitation activities directed
30 towards obtaining new work when unemployed.¹⁸
31
32
33
34
35
36
37
38
39
40
41
42
43

44 It is important to disclose predictors for long-term outcome as this may suggest
45 targets for management. We found that arthralgia at the first contact
46 independently predicted poor long-term prognosis as evaluated by employment,
47 FSS and WSAS scores. Arthralgia is a prominent and serious somatic symptom in
48 the majority of CFS patients.⁴ One may speculate that some patients with
49 arthralgia have underlying atypical chronic rheumatic disease which has not been
50
51
52
53
54
55
56
57
58
59
60

1
2
3 diagnosed. This suggests that CFS patients with arthralgia may need repeated
4
5 evaluation as to possible rheumatic disease.
6

7
8 We found that depression at the first contact tended to predict poor prognosis both
9
10 as to FSS and WSAS scores, but not employment. Pre-existing depression is an
11
12 exclusion criterion of CFS, but many patients develop co-morbid depression
13
14 reactive to the chronic illness that may contribute to a poorer prognosis due to
15
16 reduced illness coping.³⁵ In contrast to our findings another study comprising 177
17
18 patients did not find any association between depression and final outcome.³⁶
19
20

21
22 We found that FSS score at the second contact was associated with duration of
23
24 illness disease at the first contact. This is compatible to the findings in a study of
25
26 natural course in CFS.³⁷ However, there was no significant change as to
27
28 depression, arthralgia or tender lymph nodes.
29
30

31
32 As shown above reviews on predictors of prognosis show conflicting results.¹¹
33

34 This may be due to major differences between studies. Important differences
35
36 include varying number of patients, severity of disease, patient heterogeneity and
37
38 length of follow-up. Two strengths of the present study are the long-follow up
39
40 period and the relatively high response rate as to the return of the postal
41
42 questionnaire including details about occupational status. This study differ from
43
44 most others because mononucleosis was a uniform trigger of CFS in all patients.
45
46

47 One limitation of the study is that the patients were recruited from a tertiary center
48
49 and the patient cohort may represent some selection bias. Whether the written
50
51 self-management program contributed to better outcome than expected is possible.
52
53

54 This should be addressed in controlled studies in the future.
55
56
57
58
59
60

1
2
3 In conclusion, about half of younger CFS patients with long-term incapacity for
4
5 work got marked improvement including full or part-time employment. Self-
6
7 management strategies, long-term sickness absence benefits providing a stable
8
9 financial support, in addition to occupational interventions aimed at return to work
10
11 were likely contributors to the generally positive, prolonged outcome. Risk factors
12
13 for transition to permanent disability pension were depression, persistence of
14
15 arthralgia and disease duration.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 *Contributor statement:*
7

8
9 Morten Nyland: Data collection and manuscript preparation
10

11
12 Halvor Naess: Manuscript preparation and performing of analyses
13

14
15 Jon S Birkeland: Data collection and manuscript preparation
16

17
18 Harald Nyland: Data collection and manuscript preparation
19

20
21
22
23
24 Acknowledgements: none
25

26
27 Competing interests: none
28

29
30 Funding: none
31

32
33 The study was approved by the local ethics committee.
34

35
36 Data sharing is available by emailing Halvor Naess haln@haukeland.no
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med* 1994;**121**(12):953-9.
2. Salit IE. Precipitating factors for the chronic fatigue syndrome. *J Psychiatr Res* 1997;**31**(1):59-65.
3. Reeves WC, Lloyd A, Vernon SD, et al. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. *BMC health services research* 2003;**3**(1):25.
4. Vincent A, Brimmer DJ, Whipple MO, et al. Prevalence, incidence, and classification of chronic fatigue syndrome in Olmsted County, Minnesota, as estimated using the Rochester Epidemiology Project. *Mayo Clin Proc* 2012;**87**(12):1145-52.
5. Nacul LC, Lacerda EM, Pheby D, et al. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. *BMC medicine* 2011;**9**:91.
6. Wilson A, Hickie I, Hadzi-Pavlovic D, et al. What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. *The Australian and New Zealand journal of psychiatry* 2001;**35**(4):520-7.
7. Marmot M, Feeney A, Shipley M, et al. Sickness absence as a measure of health status and functioning: from the UK Whitehall II study. *J Epidemiol Community Health* 1995;**49**(2):124-30.
8. Taylor RR, Kielhofner GW. Work-related impairment and employment-focused rehabilitation options for individuals with chronic fatigue syndrome: A review. *Journal of Mental Health* 2005;**14**(3):253-67.
9. Ware NC. Sociosomatics and illness in chronic fatigue syndrome. *Psychosomatic medicine* 1998;**60**(4):394-401.
10. Ross SD, Estok RP, Frame D, et al. Disability and chronic fatigue syndrome: a focus on function. *Arch Intern Med* 2004;**164**(10):1098-107.
11. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. *Occupational medicine* 2005;**55**(1):20-31.
12. White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. *The British journal of psychiatry : the journal of mental science* 1998;**173**:475-81.
13. Katz BZ, Shiraishi Y, Mears CJ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. *Pediatrics* 2009;**124**(1):189-93.
14. Naess H, Sundal E, Myhr KM, et al. Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. *In vivo* 2010;**24**(2):185-8.
15. Nijs J, Paul L, Wallman K. Chronic fatigue syndrome: an approach combining self-management with graded exercise to avoid exacerbations. *J Rehabil Med* 2008;**40**(4):241-7.
16. Cella M, Sharpe M, Chalder T. Measuring disability in patients with chronic fatigue syndrome: reliability and validity of the Work and Social Adjustment Scale. *J Psychosom Res* 2011;**71**(3):124-8.
17. Haukenes G, Aarli JA. [Postviral fatigue syndrome]. *Tidsskr Nor Laegeforen* 1995;**115**(24):3017-22.
18. Gjesdal S, Bratberg E. Diagnosis and duration of sickness absence as predictors for disability pension: results from a three-year, multi-register based* and prospective study. *Scandinavian journal of public health* 2003;**31**(4):246-54.
19. Van Ness J, Stevent S, Bateman L, et al. Postexertional Malaise in Women with Chronic Fatigue Syndrome. *Journal of Women's Health* 2010;**19**(2):239-44.
20. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;**46**(10):1121-3.

- 1
- 2
- 3 21. Lerdal A, Wahl A, Rustoen T, et al. Fatigue in the general population: a translation and test of the
- 4 psychometric properties of the Norwegian version of the fatigue severity scale. *Scandinavian*
- 5 *journal of public health* 2005;**33**(2):123-30.
- 6 22. Mundt JC, Marks IM, Shear MK, et al. The Work and Social Adjustment Scale: a simple measure of
- 7 impairment in functioning. *The British journal of psychiatry : the journal of mental science*
- 8 2002;**180**:461-4.
- 9 23. Andersen MM, Permin H, Albrecht F. Illness and disability in Danish Chronic Fatigue Syndrome
- 10 patients at diagnosis and 5-year follow-up. *J Psychosom Res* 2004;**56**(2):217-29.
- 11 24. Vercoulen JH, Swanink CM, Fennis JF, et al. Prognosis in chronic fatigue syndrome: a prospective
- 12 study on the natural course. *J Neurol Neurosurg Psychiatry* 1996;**60**(5):489-94.
- 13 25. Tiersky LA, DeLuca J, Hill N, et al. Longitudinal assessment of neuropsychological functioning,
- 14 psychiatric status, functional disability and employment status in chronic fatigue syndrome.
- 15 *Applied neuropsychology* 2001;**8**(1):41-50.
- 16 26. Deale A, Husain K, Chalder T, et al. Long-term outcome of cognitive behavior therapy versus
- 17 relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. *The American*
- 18 *journal of psychiatry* 2001;**158**(12):2038-42.
- 19 27. Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue
- 20 syndrome: a multicentre randomised controlled trial. *Lancet* 2001;**357**(9259):841-7.
- 21 28. Bentall RP, Powell P, Nye FJ, et al. Predictors of response to treatment for chronic fatigue
- 22 syndrome. *The British journal of psychiatry : the journal of mental science* 2002;**181**:248-52.
- 23 29. McDermott C, Richards SC, Ankers s, et al. An evaluation of a chronic fatigue lifestyle
- 24 management programme focusing on the outcome of return to work or training. *British*
- 25 *Journal of Occupational Therapy* 2004;**67**(6):269-73.
- 26 30. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a
- 27 systematic review. *Qjm* 1997;**90**(3):223-33.
- 28 31. Lewis I, Pairman J, Spickett G, et al. Is chronic fatigue syndrome in older patients a different
- 29 disease? -- a clinical cohort study. *European journal of clinical investigation* 2013;**43**(3):302-8.
- 30 32. Cho HJ, Skowera A, Cleare A, et al. Chronic fatigue syndrome: an update focusing on
- 31 phenomenology and pathophysiology. *Current opinion in psychiatry* 2006;**19**(1):67-73.
- 32 33. Markussen S, Roed K, Rogeberg OJ, et al. The anatomy of absenteeism. *Journal of health*
- 33 *economics* 2011;**30**(2):277-92.
- 34 34. Akagi H, Klimes I, Bass C. Cognitive behavioral therapy for chronic fatigue syndrome in a general
- 35 hospital--feasible and effective. *General hospital psychiatry* 2001;**23**(5):254-60.
- 36 35. Lawn T, Kumar P, Knight B, et al. Psychiatric misdiagnoses in patients with chronic fatigue
- 37 syndrome. *JRSM short reports* 2010;**1**(4):28.
- 38 36. Pheley AM, Melby D, Schenck C, et al. Can we predict recovery in chronic fatigue syndrome?
- 39 *Clinical & Health Affairs* 1999;**82**:52-56.
- 40 37. van der Werf SP, de Vree B, Alberts M, et al. Natural course and predicting self-reported
- 41 improvement in patients with chronic fatigue syndrome with a relatively short illness
- 42 duration. *J Psychosom Res* 2002;**53**(3):749-53.
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Table 1 Symptoms on Contac1 and Contac2

	Contact 1	Contact 2	p
FSS score, mean (SD)	6.4 (.96)	5.0 (1.9)	<.001
Headache	61 (71)	47 (52)	.033
Myalgia	65 (72)	52 (58)	.042
Arthralgia	43 (48)	38 (42)	.45
Sleep disturbances	60 (66)	47 (52)	.048
Depression	30 (33)	25 (28)	.42
Concentration problems	83 (92)	58 (64)	<.001
Memory problems	72 (79)	51 (56)	<.001
Sore throat	48 (53)	34 (37)	.008
Tender cervical lymph nodes	17 (19)	30 (33)	.36

FSS: Fatigue Severity Score

SD: Standard deviation

Table 2 FSS score >5 or <5 on second follow-up (Contact 2) and symptoms at Contact 1

	Number of patients	FSS<5	FSS>5	P
Males	30	9 (25)	21 (39)	.17
Females	60	27 (75)	33 (61)	
Age debut of CFS		23.8 (7.9)	24.1 (7.0)	.85
Age (second control)		33.6 (7.9)	35.8 (6.9)	.17
<i>First control (Contact 1)</i>				
Age (first control)		26.8 (7.5)	29.3 (7.0)	.11
FSS score (mean)		6.3 (1.2)	6.4 (.8)	.63
Duration of CFS (yearssum , mean)		3.3 (2.4)	5.6 (4.5)	.006
Arthralgia	89	11 (33)	32 (59)	.010
Myalgia	89	24 (69)	40 (74)	.57
Headache	89	25 (71)	38 (70)	.92
Sleeping disturbances	90	23 (64)	36 (67)	.79
Depression	89	8 (23)	22 (41)	.081
Concentration problems	89	32 (91)	50 (93)	.84
Memory problems	90	30 (83)	41 (76)	.40
Sore throat	90	22 (61)	26 (48)	.23
Tender cervical lymph nodes	90	13 (36)	19 (35)	.93
Psychic stress: effect on fatigue	70			.94
None		1 (3)	1 (3)	
Worse		11 (38)	14 (35)	
Much worse		17 (59)	25 (63)	
<i>Clinical change prior to first control</i>	71			.06
Improvement		16 (55)	12 (29)	
No change		4 (14)	13 (31)	
Worsening		9 (31)	17 (40)	
<i>Education</i>	89			.08
Primary school		2 (6)	7 (13)	
High school		6 (17)	17 (32)	
College or university		28 (78)	29 (55)	

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

Table 3 FSS score >5 or <5 on second follow-up and symptoms at Contact 2

	Number of patients	FSS<5	FSS>5	P
Age (second control)	92	33.6 (7.9)	35.8 (6.9)	.17
Duration of CFS (years, mean)	90	10.1 (3.1)	12.1 (4.7)	.028
Arthralgia	90	7 (19)	31 (57)	<.001
Myalgia	90	11 (31)	41 (76)	<.001
Headache	90	11 (31)	35 (65)	.001
Sleeping disturbances	90	9 (25)	37 (69)	<.001
Depression	90	4 (11)	20 (37)	.006
Concentration problems	90	14 (39)	43 (80)	<.001
Memory problems	90	12 (33)	38 (70)	.001
Sore throat	90	12 (33)	22 (41)	.48
Tender cervical lymph nodes	90	6 (17)	24 (44)	.006

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

**Table 4 Linear regression with WSAS
as dependent variable and variables
registered at Contact 1**

	Beta	P-value
Sex	<.001	1.0
Age	.16	.17
Depression	.27	.026
Arthralgia	.25	.041
Clinical change	-.26	.031
Psychic stress	-.28	.025
Education	-.27	.021

WSAS: Work and Social Adjustment Scale

1
2
3 **Figure 1 Employment status of patients with CFS at first contact (Contact 1)**
4
5 **and follow-up (Contact 2)**
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Longitudinal follow up of employment status in patients with chronic fatigue syndrome after mononucleosis

Morten Nyland¹ cand. polit., Halvor Naess^{12*} MD, Jon Steinar Birkeland² MD, Harald Nyland¹ MD

¹ Institute of clinical medicine, University of Bergen, Bergen, Norway

² Department of Neurology, Haukeland University Hospital, Bergen, Norway

* Corresponding author

haln@haukeland.no

Department of Neurology

Haukeland University Hospital

Jonas Liesgt 65

5021 Bergen

Norway

Telephone: +4755975045

Fax: +4755975699

Key words: chronic fatigue syndrome, mononucleosis, prognosis, employment

Word count: ~~3410~~234

Field Code Changed

Abstract

Objective - To examine the effect of early clinical and demographic factors on occupational outcome, return to work or awarded permanent disability pension in young patients with chronic fatigue syndrome (CFS).

Design - Longitudinal cohort study.

Intervention - A written self-management program including a description of active coping strategies for daily life was provided.

Setting, participants - Patients with CFS after mononucleosis were evaluated at Department of Neurology, Haukeland University Hospital during 1996-2006 (~~Contact 1~~ Contact 1). In 2009 self-report questionnaires were sent to all patients (~~Contact 2~~ Contact 2).

Primary and secondary outcome measures - Primary measure was employment status ~~on at~~ ~~Contact 2~~. Secondary measures included clinical symptoms, and Fatigue Severity Scale (FSS) scores on both contacts, and Work and Social Adjustment Scale (WSAS) ~~on at~~ ~~Contact 2~~ Contact 2.

Results - Of 111 patients at ~~Contact 1~~ Contact 1, 92 (83%) patients returned the questionnaire at ~~Contact 2~~ Contact 2. Mean disease duration at ~~Contact 1~~ Contact 1 was 4.7 years and at ~~Contact 2~~ Contact 2 11.4 years. At ~~Contact 1~~ Contact 1, 9 (10%) were part or full time employed. At ~~Contact 2~~ Contact 2, 49 (55%) were part or full time employed. Logical regression analysis showed that FSS \geq 5 at ~~Contact 2~~ Contact 2 was associated with depression, arthralgia, and long disease duration (all at ~~Contact 1~~ Contact 1).

Conclusion - About half of younger CFS patients with long-term incapacity for work experienced marked improvement including full or part-time employment showing better

Formatted: Font: Not Italic

Formatted: Font: Not Italic

Formatted: Font: Not Italic

1
2
3
4
5
6
7 outcomes than expected. Risk factors for transition to permanent disability were depression,
8 arthralgia and disease duration.
9

10 **Article summary**

11 *Strengths and limitations of this study*

12
13
14 Two strengths of the study are very long prospective follow up period and focus on
15 employment.
16
17

18
19
20 A limitation is that patients were recruited from a tertiary center.
21

22
23 Long-term prognosis for young patients with CFS after mononucleosis is favorable for a large
24 subgroup.
25
26

27
28 More than half of the patients with long-term incapacity for work are re-employed after mean
29 disease duration of 11.4 years.
30

31
32 Factors associated with poor long-term prognosis include depression, arthralgia and disease
33 duration.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic fatigue syndrome (CFS) is a complex incapacitating illness of unknown cause.^{1,2} CFS is characterized by persistent/recurrent post-exertional fatigue of at least 6 months' duration accompanied by at least four of eight specific symptoms including impaired short-term memory or concentration, severe enough to cause substantial reduction in previous levels of occupational, educational, social or personal activities; headache of a new type, pattern or severity; muscle pain; multi-joint pain without swelling or redness; sore throat; tender cervical or axillary lymph nodes; unrefreshing sleep; post-exertional malaise, an exaggerated fatigue response to previous well tolerated activities.^{1,3} The clinical condition has received increased attention in the past two decades from medical, psychological and social security/insurance communities. The term "Chronic Fatigue Syndrome" was coined in 1988 by the US Centres for Disease Control (CDC) and the present case definition was developed by a joint CDC/National Institute of Health (NIH) international working group.¹ The excessive fatigue and fatigueability with disproportionately prolonged recovery after exercise or activity differentiate CFS from other fatigue conditions.

Recent population-based epidemiologic studies using the 1994 Centers for Disease Control case definition have reported the overall CFS prevalence to be 71 and 190 per 100,000 persons, respectively in Olmsted County, Minnesota and three regions of England.^{4,5} CFS occurs in individuals during peak years of employment (age 20-50) with female preponderance. Rates of unemployment are

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6 high.⁶ Work-related physical and cognitive impairments are demonstrable with
7
8 prolongation and recurrence of sickness absence episodes that can be the first step
9
10 in a process leading to prolonged medical leave and awarded disability benefits.⁷
11
12 Knowledge about the natural history and prognostic factors in CFS is important as
13
14 it relates to several aspects of the illness; information and advice to newly
15
16 diagnosed patients, planning of health care and rehabilitation strategies that focus
17
18 on volitional and social aspects of re-employment.⁸ Being unable to fulfill valued
19
20 and expected social functions, including employment, can have a dramatic impact
21
22 on their self-concept with need to re-evaluate life goals, as well as increased stress
23
24 on the part of caregivers.⁹

25
26
27 Few patient-based longitudinal studies have examined employment outcomes as
28
29 measure of prognosis in the case of CFS.^{10,11} The objectives of this prospective
30
31 study of a cohort of younger CFS patients without systematic intervention were
32
33 to document the natural course of illness and to identify predictors of work
34
35 cessation or re-entry into work force. Only patients with CFS subsequent to
36
37 mononucleosis were included in this study. The patients were given a written self-
38
39 management program including a description of active coping strategies for daily
40
41 life. A small proportion of people that develop infectious mononucleosis remain
42
43 sick with CFS.¹² A recent follow-up study of the course and outcome of CFS in
44
45 adolescents after mononucleosis showed that most individuals recover; however
46
47 13 of 301 adolescents, 4% , all female, met the criteria of CFS after 2 years.¹³

48
49 We hypothesized that baseline clinical presentations such as cognitive problems,
50
51 pain and depression at the time of referral in addition to severe fatigue and long
52
53
54
55
56
57
58
59
60

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7 illness duration prior to the evaluation predict long-term functional disability
8 including unemployment and awarded disability benefits.
9
10

24 Material and methods

27 Patients

28
29 The 111 young patients, mean age 23 year, participating in this study were part of
30 a larger cohort of 873 consecutive patients referred from all over Norway to a
31 specialist chronic fatigue clinic at the Department of Neurology, Haukeland
32 University Hospital during 1996-2006, published previously.¹⁴ All patients were
33 interviewed and examined by a specialist physician, HIN, who confirmed the
34 diagnosis of CSF meeting the Centers for Disease Control and Prevention (CDC)
35

36
37 case definition.¹ The 111 patients constitute all patients diagnosed with CSF
38 triggered by mononucleosis in the total cohort of 873 patients. The diagnosis of
39 mononucleosis was based on the physician report following the patient to our
40 clinic.
41

42
43 All received information about the illness to provide the patients with a rationale
44 and structured meaning for their illness experience. ~~A written self management~~
45 ~~program included a description of active coping strategies for daily life; graded~~
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

~~activity planning and consistent rest periods to minimize fluctuations in fatigue and symptoms as important principles for rehabilitation and occupational interventions in the local social setting. A written self-managment program included infomation about the illness to provide the patients with a rationale and structural meaning for their illness experience.¹⁵ Active coping strategies for daily life included graded activity planning; encouraging activity, but staying within their physical limitations with consistent rest periods to minimize fluctuations in fatigue and symptoms. To avoid occupational impairment and restore ability to work the importance to keep contact with the local health and rehabilitation services, and inform the employer was stressed.~~ The family doctor and the local

National Sickness Benefit Scheme office (NAV) received a specialist report on the medical history and investigations, the clinical characteristics and disability.¹⁶

The Norwegian Social and Insurance Scheme accepted CFS as a medico-legal diagnosis entitled to sickness and disability benefits to compensate for income loss in 1995.¹⁷ To receive long-term sickness absence (SA) benefits a sickness certificate has to be issued by a physician describing the cause of absence and plans for treatment. A disability pension (DP) is given to individuals aged 18 to 66 to compensate for permanent work-life exit before scheduled age retirement after relevant treatment or vocational rehabilitation.¹⁸

Primary outcome measures at long-term follow-up were employment: return to part- or full-time work, or transition to ill-health retirement and receipt of permanent disability pension. Secondary outcomes were self-rated scales of clinical change, fatigue, disability and CFS somatic symptoms.

Formatted: English (U.S.)

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

~~Contact~~ Contact 1. Initial baseline evaluation

All patients completed a questionnaire at referral that included questions about the mode of clinical onset (whether the fatigue appeared acutely or evolved gradually over months; the time from the triggering infection to debilitating fatigue defined as acute, taking days or weeks, or gradual, taking months, and duration of the illness. Questions about presenting symptoms comprised the presence or not of concentration or memory problems, throat pain, enlarged or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia, weight change, frequent micturition, photophobia, slurred vision, dizziness, tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever, increased sweating and headache.

Post-exertional malaise (PEM)¹⁹ was assessed with the following question: does physical activity influence fatigue; improving, no effect, some worsening, much worsening?

Fatigue was self-rated by the Fatigue Severity Scale (FSS)²⁰. This is a 9- item questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1, “completely disagree” to 7, “completely agree”. Examples of the items in the questionnaire are: “My motivation is lower when I am fatigued”, “Exercise brings on my fatigue” and “I am easily fatigued”. The average score of the 9 items represents the FSS score (minimum score is 1 and maximum score is 7). Patients with a mean FSS score >5 are defined as having severe fatigue.²¹

Employment status was noted as employed full-time, part-time or unemployed.

Sick leave from work or study, long term SA benefits and DP were registered.

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7 Employment or studies at the time of the triggering mononucleosis were
8 registered.
9

10
11 ~~Contact 2~~ Contact 2. Follow-up during 2009
12

13
14 Self-report questionnaires were sent to the patients in 2009 on average 6.5 years
15 after Contact 1. A clinical symptom questionnaire included questions as to
16 presence or not of problems with concentration and memory, throat pain, enlarged
17 or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia, nausea,
18 weight change, frequent micturition, photophobia, slurred vision, dizziness,
19 tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever,
20 increased sweating and headache.
21
22
23
24
25
26

27
28 The Work and Social Adjustment Scale (WSAS) was used to measure disability.

29
30 It is a five-item scale that assesses an individual's ability to perform everyday
31 activities including work, home management, family and relationship interaction,
32 and social and private leisure activities. Each of the five items was rated on a 9-
33 point scale ranging from 0 (not at all a problem) to 8 (severely impaired) so that
34 the total scores range between 0 and 40.²² The psychometric properties have been
35 validated in large CFS patient cohorts confirming that WSAS is a reliable
36 assessment tool for disability. High scores correlate with severe fatigue and poor
37 physical fitness.¹⁶
38
39
40
41
42
43
44

45
46 Fatigue was self-rated by the FFS scale. Based on change in FSS score change
47 from baseline, Contact 1, the disease course was defined; FSS change <-1 was
48 defined as worsening course; FSS change \geq -1 and \leq 1 was defined as no change;
49 FSS change >1 was defined as improvement. Self-rated global clinical outcome
50 was scored as worsening, stable, improvement and recovered. Employment status,
51
52
53
54
55
56
57
58
59
60

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7 sickness and disability benefits were recorded providing objective evidence of
8 disability. Outcome questions included the patients' rating of overall worsening or
9 improvement, and employment or disability benefit status.
10
11

12 *Statistics*

13
14 Student's t-test, chi-square test, Fisher's exact test, and pair-wise correlation test
15 were performed when appropriate. The FFS score was dichotomized and FFS
16 score ≥ 5 defined as pathological fatigue. Stepwise backward logistic regression
17 analyses were performed with dichotomized FFS score at Contact 2 as dependent
18 variable. Stepwise backward linear regression analyses with FFS at Contact 2 and
19 WSAS as dependent variables were performed. STATA 12.0 was used for
20 analyses.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

In total, 111 patients participated in the baseline evaluation (Contact 1). Postal questionnaires were completed and returned by 92 (83%) of these patients on follow-up ([Contact 2](#)); 30 (33%) males and 62 (67%) females (Contact 2). The mean age of the patients at the onset of CFS was 23.7 years (SD 7.3). Mean duration of CFS at the time of ~~Contact 1~~[Contact 1](#) was 4.7 years (SD 4.0), (median 3.2 years, inter-quartal range (IQR) 1.9 – 6.4). Mean time from debut of CFS to ~~Contact 2~~[Contact 2](#) was 11.4 years (SD 4.3) (median 10.3 years, IQR 8.5 – 13.5) (range 4.7 – 23.8). At the time of mononucleosis 43 (47%) were employed at work and 48 (52%) were students.

Employment at Contact 1

At Contact 1 nine (10.2%) patients remained employed (1 full time and 8 part time), 12 patients (13.5%) were students and 70 patients (81%) were neither employed nor studying ([missing data in one patient](#)). One patient (1%) was receiving partial DP and 7 patients (8%) were receiving full DP. Fourteen (15%) patients received partial long-term sickness absence benefits, and 62 (67%) patients received full long-term sickness absence benefits ([missing data in 8 patients](#)).

Employment at Contact 2(primary measures)

At Contact 2 twenty-four (27%) were fully employed, 25 (28%) were employed part-time and 40 (45%) were unemployed ([missing data in three patients](#)). One patient (1%) was student. Fifteen patients (17%) were awarded partial DP and 39 (44%) received full DP for the reduced working capacity. Six patients (7%) got partial sickness absence benefits and 3 patients (3%) full sickness absence

Formatted: Font: Italic

Formatted: Font: Italic

1
2
3
4
5
6
7 benefits. One (1%) unemployed patient was part time student. Five (5%) patients
8 were employed at both Contact 1 and Contact 2. [Figure 1 shows employment](#)
9 [status at Contact 1 and Contact 2.](#)

10
11
12
13 Logistic regression analyses showed that being employed ~~at on Contact at Contact~~
14 2 was associated with lack of arthralgia (OR=.3, P=.028) and reporting
15 improvement (OR=1.8, P=.062) ~~at on Contact at Contact+Contact 1~~. Another
16 [logistic](#) regression analyses showed that being employed [at Contact 2](#) was
17 associated with low FSS score ~~at on Contact at Contact~~ 2 (OR=.53, P<.001), lack of
18 arthralgia (OR=.40, P=.041), and lack of concentration problems (OR=.32,
19 P=.064), but none of the other symptoms reported at Contact 2.

26 27 *Secondary measures*

28
29
30 There was no correlation between FSS score ~~on Contact at Contact~~ 2 and degree of
31 ~~post exertional malaise PEM on Contact at Contact+Contact 1~~ (P=.57). There was
32 no correlation between mode of onset of fatigue after mononucleosis (acute or
33 taking months) and FSS score ~~on Contact at Contact~~ 2 (P=.61). Neither was there
34 any correlation between employment status ~~on Contact at Contact~~ 2 and degree of
35 ~~post exertional malaise PEM on Contact at Contact~~ 1 (P=.91) nor mode of onset
36 (P=.59). [There was no correlation between degree of PEM at Contact 1 and FSS](#)
37 [score at Contact 1 \(P=.99\).](#)

38
39
40 Based on FSS change from Contact 1 to Contact 2, 38 (44%) (FSS
41 improvement>1) improved, 42 (48%) (FSS change ≤1 and ≥-1) did not change
42 and 7 (8%) worsened (FSS change <-1). Based on self-assessment 10 (12%) had
43 worsened, 14 (17%) were stable, 47 (57%) had improved and 11 (13%) had
44 recovered ~~on Contact at Contact~~ 2.

Formatted: Font: Italic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The correlation between self-rated clinical change between ~~Contact 1~~ Contact 1 and ~~Contact 2~~ Contact 2 and employment status at Contact 2 was $r = .54$ ($P < .001$). The correlation between change in FSS from Contact 1 to Contact 2 and employment status was $r = .30$ ($P = .01$). The correlation between FSS score ~~on Contact at Contact~~ at Contact 2 and employment was $r = .51$ ($P < .001$). The correlation between WSAS score and employment was $r = .74$ ($P < .001$). The correlation between WSAS score and FSS score at Contact 2 was $r = .81$ ($P < .001$).

Clinical characteristics based on evaluation at ~~Contact 1~~ Contact 1 and ~~Contact 2~~ Contact 2 are shown in Table 1. Mean FSS score dropped from 6.4 to 5.0 ($P < .001$). CFS symptom pattern showed significant less frequencies of concentration and memory problems, headache, myalgia, sleep disturbances at Contact 2 compared to Contact 1 (all $P < .005$), but no changes as to depression and arthralgia. A comparison between patients with $FSS \geq 5$ versus $FSS < 5$ at ~~Contact 2~~ Contact 2 is shown in Table 2 and 3.

Among 26 patients who reported improvement prior to Contact 1, 25 (96%) reported further improvement at Contact 2, whereas among 38 patients who reported worsening or no change at Contact 1, 23 (61%) reported improvement at Contact 2 ($P = .001$).

Logistic regression showed that $FSS \geq 5$ (versus $FSS < 5$) ~~on Contact at Contact 2~~ was associated with the following variables registered at Contact 1: arthralgia (OR = 3.1, $P = .026$), depression (OR = 4.0, $P = .029$), duration of disease (OR = 1.2, $P = .043$), and male sex (OR = 2.6, $P = .087$). Linear regression analysis with FSS score at Contact 2 as dependent variable showed that arthralgia, depression (both

1
2
3
4
5
6
7 at Contact 1 and level of education accounted for 22% of the variation of the FSS
8 score (R-squared = .22).
9

10
11 Disability was evaluated according to the WSAS, and table 4 shows linear
12 regression with WSAS score as dependent variable and variables registered at
13 Contact 1. WSAS score was significantly associated with depression, arthralgia,
14 clinical change, psychic stress and level of education (R-squared=.28)
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Discussion**

41
42
43 Our main finding was that about half of the patients improved during the study
44 period and were fully or partly employed at the final follow-up. This shows that
45 the occupational outcome is favorable in a considerable fraction of younger CFS
46 patients after on average 5 years sickness absence from work. However, the
47 transition to partly (15 patients) or full (39 patients) permanent disability pension
48 shows that a substantial proportion develop chronic incapacity for work with
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 severe negative consequences both for the individual and for the wider society and
8
9 economy.

10
11 Few studies have examined employment status over time using operational
12
13 criteria for CFS and standardized measurements of disability and functioning to
14
15 provide information about the numbers of patients who were functionally
16
17 impaired and unable to work.¹¹ To our knowledge this study is the longest follow-

Field Code Changed

18
19 up study of CFS that has been published. Another long-term follow-up study
20
21 included 33 patients, mean age 43 year, who answered identical questionnaires at
22
23 diagnosis, after 4 years illness duration, and 5 years later. Work disability was
24
25 very high at baseline (77%) and increased to 91 % at 5-year follow-up.²³ A

Field Code Changed

26
27 prospective study including 246 patients found little improvement in occupational
28
29 status after a follow-up period of 18 months. Before onset of complaints 141
30
31 (57%) patients worked. At initial assessment 69 (28%) worked and 105 (43%)
32
33 were on sick leave or receiving disability benefits. At follow-up 71 patients (29%)
34
35 worked and 103 (42%) were on sick leave. Self-reported improvement was
36
37 indicated by 50 patients (20%), and 49 (20%) reported worsening of complaints.²⁴

Field Code Changed

38
39 Another study reported the outcome for 35 CFS patients, mean age 35 years
40
41 evaluated 42 months after the initial visit. Higher unemployment rates were found
42
43 at follow-up; 77% of patients versus 68% at baseline assessment.²⁵

Field Code Changed

44
45 A few longitudinal studies have reported employment at baseline and follow-up
46
47 after intervention. A long-term study of cognitive behavior therapy versus
48
49 relaxation therapy evaluated outcome at 5-year follow-up. A total of 68% of the
50
51 25 patients who received cognitive therapy rated themselves as improved
52
53 compared to 36% of the 28 patients who received relaxation therapy. Similar
54
55 proportions of patients were employed (56% versus 39%) but the patients in the

1
2
3
4
5
6
7 cognitive behavior group worked more hours per week (36 versus 24).²⁶ In
8 another study, cognitive behavior therapy was compared with a guided support
9 group and a natural course group at baseline and 14 months follow-up. Self-rated
10 improvement was recorded in 28/58 (50%) in the cognitive therapy group versus
11 24/76 (32%) in the natural course group. However, no treatment effect of
12 cognitive behavior therapy as compared to natural course was found on work
13 rehabilitation, only hours working in a job were measured.²⁷

Field Code Changed

14
15
16
17
18
19
20
21 A randomized controlled trial of patient education to encourage graded exercise
22 resulted in substantial self-reported improvement in physical and occupational
23 functioning compared with standard medical care. The receipt of sickness benefit
24 at the start of treatment was associated with poor outcome.²⁸ Occupational
25 therapy with a lifestyle management program was offered to 74 patients after
26 median illness duration of 5 years. At follow-up 18 months later 31 (42%) of the
27 patients had returned to new employment, voluntary work or training.²⁹

Field Code Changed

Field Code Changed

Field Code Changed

28
29
30
31
32
33
34
35 A comprehensive review of the literature on the natural course of CFS shows
36 that the illness runs a chronic course in many sufferers and that less than 10% of
37 subjects return to pre-morbid levels of functioning.³⁰ A substantial improvement
38 has, however, been observed in children in younger individuals. A recent study
39 describes variation in the CFS clinical phenotype in a group of younger patients as
40 compared to those older than 50.³¹ In addition to the observed generally positive
41 outcome for young people that study shows that CFS is a heterogeneous condition
42 of complex and multifactorial etiology.^{6,32} Return to work after long-time sickness
43 absence is a complex process influenced by the severity of the disorder, personal
44 factors, work-related factors and the compensation system.

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We found that all patients who were unemployed at the initial examination received sickness or disability benefits. Norway has been criticized for high disability payments which may undermine motivation for individuals to stay in work.³³ A poor response to treatment for CFS was predicted by being in receipt of sickness benefits in a patient education study.²⁸ In contrast, this study shows that long-term compensations to secure the socio-economic position does not inhibit return to work, but ~~are probably may be~~ essential contributors to the high proportion becoming employed at final follow-up. In addition to the financial support the contact with the social security system initiates rehabilitation activities directed towards obtaining new work when unemployed.¹⁸

Field Code Changed

Field Code Changed

Field Code Changed

It is important to disclose predictors for long-term outcome as this may suggest targets for management. We found that arthralgia at the first contact independently predicted poor long-term prognosis as evaluated by employment, FSS and WSAS scores. Arthralgia is a prominent and serious somatic symptom in the majority of CFS patients.⁴ One may speculate that some patients with arthralgia have underlying atypical chronic rheumatic disease which has not been diagnosed. This suggests that CFS patients with arthralgia may need repeated evaluation as to possible rheumatic disease.

Field Code Changed

We found that depression at the first contact tended to predict poor prognosis both as to FSS and WSAS scores, but not employment. ~~Pre-existing D~~depression is an exclusion criterion of CFS, but many patients develop co-morbid depression reactive to the chronic illness that may contribute to a poorer prognosis due to reduced illness coping. ~~Clinicians need training to be able to diagnose co-morbid psychiatric disorders, particularly depression in order to offer appropriate~~

1
2
3
4
5
6
7 ~~treatment.~~³⁵ In contrast to our findings another study comprising 177 patients did
8 not find any association between depression and final outcome.³⁶

Field Code Changed

Field Code Changed

11 We found that FSS score at the second contact was associated with duration of
12 illness disease at the first contact. This is compatible to the findings in a study of
13 natural course in CFS. ~~Patients with a relative short duration of complaints had a~~
14 ~~more favorable outcome~~³⁷. ~~Most symptoms were reported significantly less~~
15 ~~frequent on the second contact compared to the first contact.~~ However, there was
16
17
18
19
20
21 no significant change as to depression, arthralgia or tender lymph nodes.

Field Code Changed

22
23 As shown above reviews on predictors of prognosis show conflicting results.¹¹

Field Code Changed

25 This ~~is probably may be~~ due to major differences between studies. Important
26 differences include varying number of patients, severity of disease, patient
27 heterogeneity -and length of follow-up. ~~To compare studies at the very least CDC~~
28 ~~criteria should be used as well as FSS scores and data on occupational status.~~

29
30
31
32
33 Two strengths of the present study are the long-follow up period and the relatively
34 high response rate as to the return of the postal questionnaire including details
35 about occupational status. This study differ from most others because
36 mononucleosis was a uniform trigger of CFS in all patients. Another of the
37 strengths is that our patients were evaluated at two different occasions with a long
38 interval between including information on occupational status on both occasions.
39 This allowed us to predict final outcome based on factors known at the first
40 follow up. Most long term follow up studies of CFS have evaluated outcome
41 based on factors known at the final follow up. One limitation of the study is that
42
43
44
45
46
47
48
49
50
51 the patients were recruited from a tertiary center and the patient cohort may
52 represent some selection bias. Whether the written self-management program
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

contributed to better outcome than expected is possible. This should be addressed in controlled studies in the future.

In conclusion, about half of younger CFS patients with long-term incapacity for work got marked improvement including full or part-time employment. Self-management strategies, long-term sickness absence benefits providing a stable financial support, in addition to occupational interventions aimed at return to work were likely contributors to the generally positive, prolonged outcome. Risk factors for transition to permanent disability pension were depression, persistence of arthralgia and disease duration.

Contributor statement:

Morten Nyland: Data collection and manuscript preparation

Halvor Naess: Manuscript preparation and performing of analyses

Jon S Birkeland: Data collection and manuscript preparation

Harald Nyland: Data collection and manuscript preparation

Acknowledgements: none

Competing interests: none

Funding: none

The study was approved by the local ethics committee.

Data sharing is available by emailing Halvor Naess haln@haukeland.no

References

1. Fukuda K, Straus SE, Hickie J, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med* 1994;**121**(12):953-9.
2. Salit IE. Precipitating factors for the chronic fatigue syndrome. *J Psychiatr Res* 1997;**31**(1):59-65.
3. Reeves WC, Lloyd A, Vernon SD, et al. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. *BMC health services research* 2003;**3**(1):25.
4. Vincent A, Brimmer DJ, Whipple MO, et al. Prevalence, incidence, and classification of chronic fatigue syndrome in Olmsted County, Minnesota, as estimated using the Rochester Epidemiology Project. *Mayo Clin Proc* 2012;**87**(12):1145-52.

Formatted: Norwegian (Bokmål)

Field Code Changed

Formatted: Font: Calibri, Do not check spelling or grammar

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

5. Nacul LC, Lacerda EM, Pheby D, et al. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. *BMC medicine* 2011;**9**:91.
6. Wilson A, Hickie I, Hadzi-Pavlovic D, et al. What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. *The Australian and New Zealand journal of psychiatry* 2001;**35**(4):520-7.
7. Marmot M, Feeney A, Shipley M, et al. Sickness absence as a measure of health status and functioning: from the UK Whitehall II study. *J Epidemiol Community Health* 1995;**49**(2):124-30.
8. Taylor RR, Kielhofner GW. Work-related impairment and employment-focused rehabilitation options for individuals with chronic fatigue syndrome: A review. *Journal of Mental Health* 2005;**14**(3):253-67.
9. Ware NC. Sociosomatics and illness in chronic fatigue syndrome. *Psychosomatic medicine* 1998;**60**(4):394-401.
10. Ross SD, Estok RP, Frame D, et al. Disability and chronic fatigue syndrome: a focus on function. *Arch Intern Med* 2004;**164**(10):1098-107.
11. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. *Occupational medicine* 2005;**55**(1):20-31.
12. White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. *The British journal of psychiatry : the journal of mental science* 1998;**173**:475-81.
13. Katz BZ, Shiraishi Y, Mears CJ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. *Pediatrics* 2009;**124**(1):189-93.
14. Naess H, Sundal E, Myhr KM, et al. Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. *In vivo* 2010;**24**(2):185-8.
15. Nijs J, Paul L, Wallman K. Chronic fatigue syndrome: an approach combining self-management with graded exercise to avoid exacerbations. *J Rehabil Med* 2008;**40**(4):241-7.
16. Cella M, Sharpe M, Chalder T. Measuring disability in patients with chronic fatigue syndrome: reliability and validity of the Work and Social Adjustment Scale. *J Psychosom Res* 2011;**71**(3):124-8.
17. Haukenes G, Aarli JA. [Postviral fatigue syndrome]. *Tidsskr Nor Laegeforen* 1995;**115**(24):3017-22.
18. Gjesdal S, Bratberg E. Diagnosis and duration of sickness absence as predictors for disability pension: results from a three-year, multi-register based* and prospective study. *Scandinavian journal of public health* 2003;**31**(4):246-54.
19. Van Ness J, Stevent S, Bateman L, et al. Postexertional Malaise in Women with Chronic Fatigue Syndrome. *Journal of Women's Health* 2010;**19**(2):239-44.
20. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;**46**(10):1121-3.
21. Lerdal A, Wahl A, Rustoen T, et al. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. *Scandinavian journal of public health* 2005;**33**(2):123-30.
22. Mundt JC, Marks IM, Shear MK, et al. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. *The British journal of psychiatry : the journal of mental science* 2002;**180**:461-4.
23. Andersen MM, Permin H, Albrecht F. Illness and disability in Danish Chronic Fatigue Syndrome patients at diagnosis and 5-year follow-up. *J Psychosom Res* 2004;**56**(2):217-29.
24. Vercoulen JH, Swanink CM, Fennis JF, et al. Prognosis in chronic fatigue syndrome: a prospective study on the natural course. *J Neurol Neurosurg Psychiatry* 1996;**60**(5):489-94.
25. Tiersky LA, DeLuca J, Hill N, et al. Longitudinal assessment of neuropsychological functioning, psychiatric status, functional disability and employment status in chronic fatigue syndrome. *Applied neuropsychology* 2001;**8**(1):41-50.

Formatted: Font: Calibri, Do not check spelling or grammar

Formatted: Norwegian (Bokmål)

Formatted: Font: Calibri, Do not check spelling or grammar

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
26. Deale A, Husain K, Chalder T, et al. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. *The American journal of psychiatry* 2001;**158**(12):2038-42.
 27. Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. *Lancet* 2001;**357**(9259):841-7.
 28. Bentall RP, Powell P, Nye FJ, et al. Predictors of response to treatment for chronic fatigue syndrome. *The British journal of psychiatry : the journal of mental science* 2002;**181**:248-52.
 29. McDermott C, Richards SC, Ankers s, et al. An evaluation of a chronic fatigue lifestyle management programme focusing on the outcome of return to work or training. *British Journal of Occupational Therapy* 2004;**67**(6):269-73.
 30. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. *Qjm* 1997;**90**(3):223-33.
 31. Lewis I, Pairman J, Spickett G, et al. Is chronic fatigue syndrome in older patients a different disease? -- a clinical cohort study. *European journal of clinical investigation* 2013;**43**(3):302-8.
 32. Cho HJ, Skowera A, Cleare A, et al. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. *Current opinion in psychiatry* 2006;**19**(1):67-73.
 33. Markussen S, Roed K, Rogeberg OJ, et al. The anatomy of absenteeism. *Journal of health economics* 2011;**30**(2):277-92.
 34. Akagi H, Klimes I, Bass C. Cognitive behavioral therapy for chronic fatigue syndrome in a general hospital--feasible and effective. *General hospital psychiatry* 2001;**23**(5):254-60.
 35. Lawn T, Kumar P, Knight B, et al. Psychiatric misdiagnoses in patients with chronic fatigue syndrome. *JRSM short reports* 2010;**1**(4):28.
 36. Pheley AM, Melby D, Schenck C, et al. Can we predict recovery in chronic fatigue syndrome? *Clinical & Health Affairs* 1999;**82**:52-56.
 37. van der Werf SP, de Vree B, Alberts M, et al. Natural course and predicting self-reported improvement in patients with chronic fatigue syndrome with a relatively short illness duration. *J Psychosom Res* 2002;**53**(3):749-53.

33 **Table 1 Symptoms on Contact1 and Contact2**

	Contact1	Contact 2	p
FSS score, mean (SD)	6.4 (.96)	5.0 (1.9)	<.001
Headache	61 (71)	47 (52)	.033
Myalgia	65 (72)	52 (58)	.042
Arthralgia	43 (48)	38 (42)	.45
Sleep disturbances	60 (66)	47 (52)	.048
Depression	30 (33)	25 (28)	.42
Concentration problems	83 (92)	58 (64)	<.001
Memory problems	72 (79)	51 (56)	<.001
Sore throat	48 (53)	34 (37)	.008
Tender cervical lymph nodes	17 (19)	30 (33)	.36

50 FSS: Fatigue Severity Score

51 SD: Standard deviation

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

**Table 2 FSS score >5 or <5 on second follow-up (Contact 2) and symptoms ~~on Contact 2~~
Contact 1**

	Number of patients	FSS<5	FSS>5	P
Males	30	9 (25)	21 (39)	.17
Females	60	27 (75)	33 (61)	
Age debut of CFS		23.8 (7.9)	24.1 (7.0)	.85
Age (second control)		33.6 (7.9)	35.8 (6.9)	.17
<i>First control (<u>Contact 1</u>)</i>				
Age (first control)		26.8 (7.5)	29.3 (7.0)	.11
FSS score (mean)		6.3 (1.2)	6.4 (.8)	.63
Duration of CFS (yearssum , mean)		3.3 (2.4)	5.6 (4.5)	.006
Arthralgia	89	11 (33)	32 (59)	.010
Myalgia	89	24 (69)	40 (74)	.57
Headache	89	25 (71)	38 (70)	.92
Sleeping disturbances	90	23 (64)	36 (67)	.79

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Depression	89	8 (23)	22 (41)	.081
Concentration problems	89	32 (91)	50 (93)	.84
Memory problems	90	30 (83)	41 (76)	.40
<u>Sore throat</u>	<u>90</u>	<u>22 (61)</u>	<u>26 (48)</u>	<u>.23</u>
<u>Tender cervical lymph nodes</u>	<u>90</u>	<u>13 (36)</u>	<u>19 (35)</u>	<u>.93</u>
<u>Psychic stress: effect on fatigue</u>	<u>70</u>			<u>.94</u>
<u>None</u>		<u>1 (3)</u>	<u>1 (3)</u>	
<u>Worse</u>		<u>11 (38)</u>	<u>14 (35)</u>	
<u>Much worse</u>		<u>17 (59)</u>	<u>25 (63)</u>	
<u>Clinical change prior to first control</u>	<u>71</u>			<u>.06</u>
Improvement		16 (55)	12 (29)	
No change		4 (14)	13 (31)	
Worsening		9 (31)	17 (40)	
<u>Education</u>	<u>89</u>			<u>.08</u>
<u>Primary school</u>		<u>2 (6)</u>	<u>7 (13)</u>	
<u>High school</u>		<u>6 (17)</u>	<u>17 (32)</u>	
<u>College or university</u>		<u>28 (78)</u>	<u>29 (55)</u>	

Formatted: Font: Not Italic

Formatted: Font: Italic

Formatted Table

Formatted: Font: Italic

FSS: Fatigue Severity Scale
CFS: Chronic fatigue syndrome

**Table 3 FSS score >5 or <5 on second follow-up and symptoms ~~on-Contactat~~
Contact2>Contact 2**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Number of patients	FSS<5	FSS>5	P
Age (second control)	92	33.6 (7.9)	35.8 (6.9)	.17
Duration of CFS (years, mean)	90	10.1 (3.1)	12.1 (4.7)	.028
Arthralgia	90	7 (19)	31 (57)	<.001
Myalgia	90	11 (31)	41 (76)	<.001
Headache	90	11 (31)	35 (65)	.001
Sleeping disturbances	90	9 (25)	37 (69)	<.001
Depression	90	4 (11)	20 (37)	.006
Concentration problems	90	14 (39)	43 (80)	<.001
Memory problems	90	12 (33)	38 (70)	.001
<u>Sore throat</u>	<u>90</u>	<u>12 (33)</u>	<u>22 (41)</u>	<u>.48</u>
<u>Tender cervical lymph nodes</u>	<u>90</u>	<u>6 (17)</u>	<u>24 (44)</u>	<u>.006</u>

Formatted: Right: 2.16"

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15 **Table 4 Linear regression with WSAS**

16 as dependent variable and variables
17 registered at [Contact 1](#)
18 [Contact 1](#)
19


	Beta	P-value
Sex	<.001	1.0
Age	.16	.17
Depression	.27	.026
Arthralgia	.25	.041
Clinical change	-.26	.031
Psychic stress	-.28	.025
Education	-.27	.021

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36 WSAS: Work and Social Adjustment Scale
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 Employment status of patients with CFS at first contact (Contact 1) and follow-up (Contact 2)

Formatted: Font: Bold




review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

|

For peer review only



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies


Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-9
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	10
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	10-11 10-11
Outcome data	15*	Report numbers of outcome events or summary measures over time	10-12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



122x67mm (300 x 300 DPI)

review only

BMJ Open

Longitudinal follow up of employment status in patients with chronic fatigue syndrome after mononucleosis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005798.R2
Article Type:	Research
Date Submitted by the Author:	31-Oct-2014
Complete List of Authors:	Nyland, Morten; Haukeland Universiyt Hospital, Neurology Naess, Halvor; Haukeland University Hospital, Neurology Birkeland, Jon; Haukeland Universiyt Hospital, Neurology Nyland, Harald; Haukeland Universiyt Hospital, Neurology
Primary Subject Heading:	Health economics
Secondary Subject Heading:	Health economics, Infectious diseases
Keywords:	Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Infectious disease/HIV < NEUROLOGY, OCCUPATIONAL & INDUSTRIAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 Longitudinal follow up of employment status in patients with chronic
4 fatigue syndrome after mononucleosis
5
6
7
8

9 **Morten Nyland¹ cand. polit., Halvor Naess^{12*} MD, Jon Steinar Birkeland² MD, Harald**
10 **Nyland¹ MD**
11

12
13
14
15 ¹ Institute of clinical medicine, University of Bergen, Bergen, Norway

16
17 ² Department of Neurology, Haukeland University Hospital, Bergen, Norway
18
19

20
21 * Corresponding author

22 haln@haukeland.no
23

24 Department of Neurology
25

26 Haukeland University Hospital
27

28 Jonas Liesgt 65
29

30 5021 Bergen
31

32 Norway
33

34 Telephone: +4755975045
35

36 Fax: +4755975699
37
38
39
40
41
42

43 Key words: chronic fatigue syndrome, mononucleosis, prognosis, employment
44

45 Word count: 3410
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective - To examine the effect of early clinical and demographic factors on occupational outcome, return to work or awarded permanent disability pension in young patients with chronic fatigue syndrome (CFS).

Design - Longitudinal cohort study.

Intervention - A written self-management program including a description of active coping strategies for daily life was provided.

Setting, participants - Patients with CFS after mononucleosis were evaluated at Department of Neurology, Haukeland University Hospital during 1996-2006 (Contact 1). In 2009 self-report questionnaires were sent to all patients (Contact 2).

Primary and secondary outcome measures - Primary measure was employment status at Contact 2. Secondary measures included clinical symptoms, and Fatigue Severity Scale (FSS) scores on both contacts, and Work and Social Adjustment Scale (WSAS) at Contact 2.

Results - Of 111 patients at Contact 1, 92 (83%) patients returned the questionnaire at Contact 2. Mean disease duration at Contact 1 was 4.7 years and at Contact 2 11.4 years. At Contact 1, 9 (10%) were part or full time employed. At Contact 2, 49 (55%) were part or full time employed. Logical regression analysis showed that $FSS \geq 5$ at Contact 2 was associated with depression, arthralgia, and long disease duration (all at Contact 1).

Conclusion - About half of younger CFS patients with long-term incapacity for work experienced marked improvement including full or part-time employment showing better outcomes than expected. Risk factors for transition to permanent disability were depression, arthralgia and disease duration.

1
2
3 **Article summary**
4

5
6 *Strengths and limitations of this study*
7

8
9 Two strengths of the study are very long prospective follow up period and focus on
10
11 employment.
12

13
14 A limitation is that patients were recruited from a tertiary center.
15

16
17 Long-term prognosis for young patients with CFS after mononucleosis is favorable for a large
18
19 subgroup.
20

21
22 More than half of the patients with long-term incapacity for work are re-employed after mean
23
24 disease duration of 11.4 years.
25

26
27 Factors associated with poor long-term prognosis include depression, arthralgia and disease
28
29 duration.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic fatigue syndrome (CFS) is a complex incapacitating illness of unknown cause.^{1 2} CFS is characterized by persistent/recurrent post-exertional fatigue of at least 6 months' duration accompanied by at least four of eight specific symptoms including impaired short-term memory or concentration, severe enough to cause substantial reduction in previous levels of occupational, educational, social or personal activities; headache of a new type, pattern or severity; muscle pain; multi-joint pain without swelling or redness; sore throat; tender cervical or axillary lymph nodes; unrefreshing sleep; post-exertional malaise, an exaggerated fatigue response to previous well tolerated activities.^{1 3} The clinical condition has received increased attention in the past two decades from medical, psychological and social security/insurance communities. The term ``Chronic Fatigue Syndrome`` was coined in 1988 by the US Centers for Disease Control (CDC) and the present case definition was developed by a joint CDC/National Institute of Health (NIH) international working group.¹ The excessive fatigue and fatigue-ability with disproportionately prolonged recovery after exercise or activity differentiate CFS from other fatigue conditions.

Recent population-based epidemiologic studies using the 1994 CDC case definition have reported the overall CFS prevalence to be 71 and 190 per 100,000 persons, respectively in Olmsted County, Minnesota and three regions of England.^{4 5} CFS occurs in individuals during peak years of employment (age 20-50) with female preponderance. Rates of unemployment are high.⁶ Work-related physical and cognitive impairments are demonstrable with prolongation and recurrence of sickness absence episodes that can be the first step in a process leading to prolonged medical leave and awarded disability benefits.⁷

1
2
3 A small proportion of people that develop infectious mononucleosis remain sick
4
5 with CFS.⁸ A recent follow-up study of the course and outcome of CFS in
6
7 adolescents after mononucleosis showed that most individuals recover; however
8
9 13 of 301 adolescents, 4% , all female, met the criteria of CFS after 2 years.⁹

10
11
12 Knowledge about the natural history and prognostic factors in CFS is important as
13
14 it relates to several aspects of the illness; information and advice to newly
15
16 diagnosed patients, planning of health care and rehabilitation strategies that focus
17
18 on volitional and social aspects of re-employment.¹⁰ Being unable to fulfill valued
19
20 and expected social functions, including employment, can have a dramatic impact
21
22 on self-concept with need to re-evaluate life goals, as well as increased stress on
23
24 the part of caregivers.¹¹

25
26
27
28
29 Few patient-based longitudinal studies have examined employment outcomes as
30
31 measure of prognosis in the case of CFS.^{12 13} The objectives of this two time point
32
33 study of a cohort of younger CFS patients without systematic intervention were
34
35 to document the natural course of illness and to identify predictors of work
36
37 cessation or re-entry into work force. Only patients with CFS subsequent to
38
39 mononucleosis were included in this study.

40
41
42
43 We hypothesized that baseline clinical presentations such as cognitive problems,
44
45 pain and depression at the time of referral in addition to severe fatigue and long
46
47 illness duration prior to the evaluation predict long-term functional disability
48
49 including unemployment and awarded disability benefits.

Material and methods

Patients

The 111 young patients, mean age 23 year, participating in this study were part of a larger cohort of 873 consecutive patients referred from all over Norway to a specialist chronic fatigue clinic at the Department of Neurology, Haukeland University Hospital during 1996-2006, published previously.¹⁴ All patients were interviewed and examined by a specialist physician, HIN, who confirmed the diagnosis of CSF meeting the Centers for Disease Control and Prevention (CDC) case definition.¹ The 111 patients constitute all patients diagnosed with CSF triggered by mononucleosis in the total cohort of 873 patients. The diagnosis of mononucleosis was based on the physician report following the patient to our clinic.

A written self-management program included information about the illness to provide the patients with a rationale and structural meaning for their illness experience.¹⁵ Active coping strategies for daily life included graded activity planning; encouraging activity, but staying within their physical limitations with consistent rest periods to minimize fluctuations in fatigue and symptoms. To avoid occupational impairment and restore ability to work the importance to keep contact with the local health and rehabilitation services, and inform the employer was stressed. The family doctor and the local National Sickness Benefit Scheme office (NAV) received a specialist report on the medical history and investigations, the clinical characteristics and disability.¹⁶

The Norwegian Social and Insurance Scheme accepted CFS as a medico-legal diagnosis entitled to sickness and disability benefits to compensate for income

1
2
3 loss in 1995.¹⁷ To receive long-term sickness absence (SA) benefits a sickness
4 certificate has to be issued by a physician describing the cause of absence and
5 plans for treatment. A disability pension (DP) is given to individuals aged 18 to
6 66 to compensate for permanent work-life exit before scheduled age retirement
7 after relevant treatment or vocational rehabilitation.¹⁸
8
9

10
11
12 Primary outcome measures at long-term follow-up were employment: return to
13 part- or full-time work, or transition to ill-health retirement and receipt of
14 permanent disability pension. Secondary outcomes were self-rated scales of
15 clinical change, fatigue, disability and CFS somatic symptoms.
16
17
18
19
20
21
22

23 24 *Contact 1. Initial baseline evaluation* 25

26
27 All patients completed a questionnaire at referral that included questions about the
28 mode of clinical onset (whether the fatigue appeared acutely or evolved gradually
29 over months) and duration of the illness. Questions about presenting symptoms
30 comprised the presence or not of concentration or memory problems, throat pain,
31 enlarged or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia,
32 weight change, frequent micturition, photophobia, slurred vision, dizziness,
33 tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever,
34 increased sweating and headache. Post-exertional malaise (PEM)¹⁹ was assessed
35 with the following question: does physical activity influence fatigue; improving,
36 no effect, some worsening, much worsening?
37
38
39
40
41
42
43
44
45
46
47
48

49
50 Fatigue was self-rated by the Fatigue Severity Scale (FSS).²⁰ This is a 9- item
51 questionnaire that assesses the effect of fatigue on daily living. Each item is a
52 statement on fatigue that the subject rates from 1, “completely disagree” to 7,
53 “completely agree”. Examples of the items in the questionnaire are: “My
54
55
56
57
58
59
60

1
2
3 motivation is lower when I am fatigued”, “Exercise brings on my fatigue” and “I
4 am easily fatigued”. The average score of the 9 items represents the FSS score
5 (minimum score is 1 and maximum score is 7). Patients with a mean FSS score >5
6
7 are defined as having severe fatigue.²¹
8
9

10
11
12 Employment status was noted as employed full-time, part-time or unemployed.

13
14 Sick leave from work or study, long term SA benefits and DP were registered.

15
16 Employment or studies at the time of the triggering mononucleosis were
17
18 registered.
19

20 21 22 *Contact 2. Follow-up during 2009* 23

24
25 Self-report questionnaires were sent to the patients in 2009 on average 6.5 years
26
27 after Contact 1. A clinical symptom questionnaire included questions as to
28
29 presence or not of problems with concentration and memory, throat pain, enlarged
30
31 or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia, nausea,
32
33 weight change, frequent micturition, photophobia, slurred vision, dizziness,
34
35 tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever,
36
37 increased sweating and headache.
38

39
40
41 The Work and Social Adjustment Scale (WSAS) was used to measure disability.
42
43 It is a five-item scale that assesses an individual’s ability to perform everyday
44
45 activities including work, home management, family and relationship interaction,
46
47 and social and private leisure activities. Each of the five items was rated on a 9-
48
49 point scale ranging from 0 (not at all a problem) to 8 (severely impaired) so that
50
51 the total scores range between 0 and 40.²² The psychometric properties have been
52
53 validated in large CFS patient cohorts confirming that WSAS is a reliable
54
55
56
57
58
59
60

1
2
3 assessment tool for disability. High scores correlate with severe fatigue and poor
4
5 physical fitness.¹⁶
6
7

8 Fatigue was self-rated by the FSS scale. Based on change in FSS score change
9
10 from baseline, Contact 1, the disease course was defined; FSS change <-1 was
11
12 defined as worsening course; FSS change \geq -1 and \leq 1 was defined as no change;
13
14 FSS change >1 was defined as improvement. Self-rated global clinical outcome
15
16 was scored as worsening, stable, improvement and recovered. Employment status,
17
18 sickness and disability benefits were recorded providing objective evidence of
19
20 disability.
21
22

23
24 The study was approved by the local ethics committee. Informed, written consent
25
26 was obtained from the patients.
27
28

29 *Statistics*

30
31
32 Student's t-test, chi-square test, Fisher's exact test, and pair-wise correlation test
33
34 were performed when appropriate. The FSS score was dichotomized and FSS
35
36 score \geq 5 defined as pathological fatigue. Stepwise backward logistic regression
37
38 analyses were performed with dichotomized FSS score at Contact 2 as dependent
39
40 variable. Stepwise backward linear regression analyses with FSS at Contact 2 and
41
42 WSAS as dependent variables were performed. STATA 12.0 was used for
43
44 analyses.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

In total, 111 patients participated in the baseline evaluation . Postal questionnaires were completed and returned by 92 (83%) of these patients on follow-up (Contact 2); 30 (33%) males and 62 (67%) females (Contact 2). The mean age of the patients at the onset of CFS was 23.7 years (SD 7.3). Mean duration of CFS at the time of Contact 1 was 4.7 years (SD 4.0), (median 3.2 years, inter-quartile range (IQR) 1.9 – 6.4). Mean time from debut of CFS to Contact 2 was 11.4 years (SD 4.3) (median 10.3 years, IQR 8.5 – 13.5) (range 4.7 – 23.8). At the time of mononucleosis 43 (47%) were employed at work and 48 (52%) were students (missing data in one patient). We do not report any data on the 19 (17%) who did not complete the follow-up.

Employment at Contact 1(92 patients)

At Contact 1 nine (10.2%) patients remained employed (1 full time and 8 part time), 12 patients (13.5%) were students and 70 patients (81%) were neither employed nor studying (missing data in one patient). One patient (1%) was receiving partial DP and 7 patients (8%) were receiving full DP. Fourteen (15%) patients received partial long-term SA benefits, and 62 (67%) patients received full long-term sickness SA (missing data in 8 patients).

Employment at Contact 2(primary measures)(92 patients)

At Contact 2 twenty-four (27%) were fully employed, 25 (28%) were employed part-time and 40 (45%) were unemployed (missing data in three patients). One patient (1%) was student. In total, 63 of 92 patients received DP or sickness absence benefits: 15 patients (17%) were awarded partial DP and 39 (44%) received full DP for the reduced working capacity, 6 patients (7%) got partial SA

1
2
3 benefits and 3 patients (3%) full SA benefits. One (1%) unemployed patient was
4
5 part time student. Five (5%) patients were employed at both Contact 1 and
6
7 Contact 2. Figure 1 shows employment status at Contact 1 and Contact 2.
8
9

10
11 Logistic regression analyses showed that being employed at Contact 2 was
12
13 associated with lack of arthralgia (OR=.3, P=.028) and reporting improvement
14
15 (OR=1.8, P=.062) at Contact 1. Another logistic regression analyses showed that
16
17 being employed at Contact 2 was associated with low FSS score at Contact 2
18
19 (OR=.53, P<.001), lack of arthralgia (OR=.40, P=.041), and lack of concentration
20
21 problems (OR=.32, P=.064), but none of the other symptoms reported at Contact
22
23 2.
24
25

26 27 *Secondary measures*

28
29 There was no correlation between FSS score at Contact 2 and degree of PEM at
30
31 Contact 1 (P=.57). There was no correlation between mode of onset of fatigue
32
33 after mononucleosis (acute or taking months) and FSS score at Contact 2 (P=.61).
34
35 Neither was there any correlation between employment status at Contact 2 and
36
37 degree of PEM at Contact 1 (P=.91) nor mode of onset (P=.59). There was no
38
39 correlation between degree of PEM at Contact 1 and FSS score at Contact 1
40
41 (P=.99).
42
43
44

45
46 Based on FSS change from Contact 1 to Contact 2, 38 (44%) (FSS
47
48 improvement >1) improved, 42 (48%) (FSS change ≤ 1 and ≥ -1) did not change
49
50 and 7 (8%) worsened (FSS change <-1). Based on self-assessment 10 (12%) had
51
52 worsened, 14 (17%) were stable, 47 (57%) had improved and 11 (13%) had
53
54 recovered at Contact 2.
55
56
57
58
59
60

1
2
3 The correlation between self-rated clinical change between Contact 1 and Contact
4
5 2 and employment status at Contact 2 was $r = .54$ ($P < .001$). The correlation
6
7 between change in FSS from Contact 1 to Contact 2 and employment status was
8
9 $r = .30$ ($P = .01$). The correlation between FSS score at Contact 2 and employment
10
11 was $r = .51$ ($P < .001$). The correlation between WSAS score and employment was
12
13 $r = .74$ ($P < .001$). The correlation between WSAS score and FSS score at Contact 2
14
15 was $r = .81$ ($P < .001$).
16
17

18
19 Clinical characteristics based on evaluation at Contact 1 and Contact 2 are shown
20
21 in Table 1. Mean FSS score dropped from 6.4 to 5.0 ($P < .001$). CFS symptom
22
23 pattern showed significant less frequencies of concentration and memory
24
25 problems, headache, myalgia, sleep disturbances at Contact 2 compared to
26
27 Contact 1 (all $P < .005$), but no changes as to depression and arthralgia. A
28
29 comparison between patients with $FSS \geq 5$ versus $FSS < 5$ at Contact 2 is shown in
30
31 Table 2 and 3.
32
33

34
35 Among 26 patients who reported improvement prior to Contact 1, 25 (96%)
36
37 reported further improvement at Contact 2, whereas among 38 patients who
38
39 reported worsening or no change at Contact 1, 23 (61%) reported improvement at
40
41 Contact 2 ($P = .001$).
42
43

44
45 Logistic regression showed that $FSS \geq 5$ (versus $FSS < 5$) at Contact 2 was
46
47 associated with the following variables registered at Contact 1: arthralgia (OR=
48
49 3.1, $P = .026$), depression (OR=4.0, $P = .029$), duration of disease (OR=1.2, $P = .043$),
50
51 and male sex (OR=2.6, $P = .087$). Linear regression analysis with FSS score at
52
53 Contact 2 as dependent variable showed that arthralgia, depression (both at
54
55
56
57
58
59
60

1
2
3 Contact 1) and level of education accounted for 22% of the variation of the FSS
4
5 score (R-squared = .22).
6
7

8 Disability was evaluated according to the WSAS, and Table 4 shows linear
9
10 regression with WSAS score as dependent variable and variables registered at
11
12 Contact 1. WSAS score was significantly associated with depression, arthralgia,
13
14 clinical change, psychic stress and level of education (R-squared=.28)
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Our main finding was that about half of the patients improved during the study period and were fully or partly employed at the final follow-up. This shows that the occupational outcome is favorable in a considerable fraction of younger CFS patients after on average 5 years sickness absence from work. However, the transition to partly (15 patients) or full (39 patients) permanent disability pension shows that a substantial proportion develop chronic incapacity for work with severe negative consequences both for the individual and for the wider society and economy.

Few studies have examined employment status over time using operational criteria for CFS and standardized measurements of disability and functioning to provide information about the numbers of patients who were functionally impaired and unable to work.¹³ To our knowledge this study is the longest follow-up study of CFS that has been published. Table 5 describes 6 studies that examined work status over time. A long-term follow-up study included 33 patients, mean age 43 year, who answered identical questionnaires at diagnosis, after 4 years illness duration, and 5 years later. Work disability was very high at baseline (77%) and increased to 91 % at 5-year follow-up.²³ A prospective study including 246 patients found little improvement in occupational status after a follow-up period of 18 months. Before onset of complaints 141 (57%) patients worked. At initial assessment 69 (28%) worked and 105 (43%) were on sick leave or receiving disability benefits. At follow-up 71 patients (29%) worked and 103 (42%) were on sick leave. Self-reported improvement was indicated by 50 patients (20%), and 49 (20%) reported worsening of complaints.²⁴ Another study reported the outcome for 35 CFS patients (mean age 35 years) evaluated 42

1
2
3 months after the initial visit. Higher unemployment rates were found at follow-up;
4
5 77% of patients versus 68% at baseline assessment.²⁵
6
7

8 A few longitudinal studies have reported employment at baseline and follow-up
9
10 after intervention. A long-term study of cognitive behavior therapy versus
11
12 relaxation therapy evaluated outcome at 5-year follow-up. A total of 68% of the
13
14 25 patients who received cognitive therapy rated themselves as improved
15
16 compared to 36% of the 28 patients who received relaxation therapy. Similar
17
18 proportions of patients were employed (56% versus 39%) but the patients in the
19
20 cognitive behavior group worked more hours per week (36 versus 24).²⁶ In
21
22 another study no treatment effect of cognitive behavior therapy as compared to
23
24 natural course was found on work rehabilitation although self-rated improvement
25
26 was associated with cognitive behavior treatment.²⁷
27
28
29

30
31 A randomized controlled trial of patient education to encourage graded exercise
32
33 resulted in substantial self-reported improvement in physical and occupational
34
35 functioning compared with standard medical care. The receipt of sickness benefit
36
37 at the start of treatment was associated with poor outcome.²⁸ Occupational
38
39 therapy with a lifestyle management program was offered to 74 patients after
40
41 median illness duration of 5 years. At follow-up 18 months later 31 (42%) of the
42
43 patients had returned to new employment, voluntary work or training.²⁹
44
45
46

47 A comprehensive review of the literature on the natural course of CFS shows
48
49 that the illness run a chronic course in many sufferers and that less than 10% of
50
51 subjects return to pre-morbid levels of functioning.³⁰ Return to work after long-
52
53 time sickness absence is a complex process influenced by the severity of the
54
55 disorder, personal factors, work-related factors and the compensation system.
56
57
58
59
60

1
2
3 We found that all patients who were unemployed at the initial examination
4
5 received sickness or disability benefits. Norway has been criticized for high
6
7 disability payments which may undermine motivation for individuals to stay in
8
9 work.³¹ A poor response to treatment for CFS was predicted by being in receipt of
10
11 sickness benefits in a patient education study.²⁸ In contrast, this study shows that
12
13 long-term compensations to secure the socio-economic position does not inhibit
14
15 return to work, but may be essential contributors to the high proportion
16
17 becoming employed at final follow-up. In addition to the financial support the
18
19 contact with the social security system initiates rehabilitation activities directed
20
21 towards obtaining new work when unemployed.¹⁸
22
23
24
25

26 It is important to disclose predictors for long-term outcome as this may suggest
27
28 targets for management. We found that arthralgia at the first contact
29
30 independently predicted poor long-term prognosis as evaluated by employment,
31
32 FSS and WSAS scores. Arthralgia is a prominent and serious somatic symptom in
33
34 the majority of CFS patients.⁴ We found that depression at the first contact tended
35
36 to predict poor prognosis both as to FSS and WSAS scores, but not employment.
37
38 Pre-existing depression is an exclusion criterion of CFS, but many patients
39
40 develop co-morbid depression reactive to the chronic illness that may contribute
41
42 to a poorer prognosis due to reduced illness coping.³² In contrast to our findings
43
44 another study comprising 177 patients did not find any association between
45
46 depression and final outcome.³³
47
48
49
50

51 We found that FSS score at the second contact was associated with duration of
52
53 illness disease at the first contact. This is compatible to the findings in a study of
54
55 natural course in CFS.³⁴ As shown above reviews on predictors of prognosis
56
57 show conflicting results.¹³ This may be due to major differences between studies.
58
59
60

1
2
3 Important differences include varying number of patients, severity of disease,
4
5 patient heterogeneity and length of follow-up. Two strengths of the present study
6
7 are the long-follow up period and the relatively high response rate as to the return
8
9 of the postal questionnaire including details about occupational status. This study
10
11 differs from most others because mononucleosis was a uniform trigger of CFS in
12
13 all patients. One limitation of the study is that the patients were recruited from a
14
15 tertiary center and the patient cohort may represent some selection bias. Whether
16
17 the written self-management program contributed to better outcome than expected
18
19 is possible. This should be addressed in controlled studies in the future.
20
21
22

23
24 In conclusion, about half of younger CFS patients with long-term incapacity for
25
26 work got marked improvement including full or part-time employment. Self-
27
28 management strategies, long-term sickness absence benefits providing a stable
29
30 financial support, in addition to occupational interventions aimed at return to work
31
32 were likely contributors to the generally positive, prolonged outcome. Risk factors
33
34 for transition to permanent disability pension were depression, persistence of
35
36 arthralgia and disease duration.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 *Contributor statement:*
7

8
9 Morten Nyland: Data collection, manuscript preparation and revisions
10

11
12 Halvor Naess: Manuscript preparation, revisions and performing of analyses
13

14
15 Jon S Birkeland: Data collection and manuscript preparation
16

17
18 Harald Nyland: Data collection, manuscript preparation and revisions
19

20
21 All have approved the present revision.
22
23

24
25
26
27 Acknowledgements: none
28

29
30 Competing interests: none
31

32
33 Funding: none
34

35
36 The study was approved by the local ethics committee.
37
38

39
40 Data sharing: No additional data available.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med* 1994;**121**(12):953-9.
2. Salit IE. Precipitating factors for the chronic fatigue syndrome. *J Psychiatr Res* 1997;**31**(1):59-65.
3. Reeves WC, Lloyd A, Vernon SD, et al. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. *BMC health services research* 2003;**3**(1):25.
4. Vincent A, Brimmer DJ, Whipple MO, et al. Prevalence, incidence, and classification of chronic fatigue syndrome in Olmsted County, Minnesota, as estimated using the Rochester Epidemiology Project. *Mayo Clin Proc* 2012;**87**(12):1145-52.
5. Nacul LC, Lacerda EM, Pheby D, et al. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. *BMC medicine* 2011;**9**:91.
6. Wilson A, Hickie I, Hadzi-Pavlovic D, et al. What is chronic fatigue syndrome? Heterogeneity within an international multicentre study. *The Australian and New Zealand journal of psychiatry* 2001;**35**(4):520-7.
7. Marmot M, Feeney A, Shipley M, et al. Sickness absence as a measure of health status and functioning: from the UK Whitehall II study. *J Epidemiol Community Health* 1995;**49**(2):124-30.
8. White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. *The British journal of psychiatry : the journal of mental science* 1998;**173**:475-81.
9. Katz BZ, Shiraishi Y, Mears CJ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. *Pediatrics* 2009;**124**(1):189-93.
10. Taylor RR, Kielhofner GW. Work-related impairment and employment-focused rehabilitation options for individuals with chronic fatigue syndrome: A review. *Journal of Mental Health* 2005;**14**(3):253-67.
11. Ware NC. Sociosomatics and illness in chronic fatigue syndrome. *Psychosomatic medicine* 1998;**60**(4):394-401.
12. Ross SD, Estok RP, Frame D, et al. Disability and chronic fatigue syndrome: a focus on function. *Arch Intern Med* 2004;**164**(10):1098-107.
13. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. *Occupational medicine* 2005;**55**(1):20-31.
14. Naess H, Sundal E, Myhr KM, et al. Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. *In vivo* 2010;**24**(2):185-8.
15. Nijs J, Paul L, Wallman K. Chronic fatigue syndrome: an approach combining self-management with graded exercise to avoid exacerbations. *J Rehabil Med* 2008;**40**(4):241-7.
16. Cella M, Sharpe M, Chalder T. Measuring disability in patients with chronic fatigue syndrome: reliability and validity of the Work and Social Adjustment Scale. *J Psychosom Res* 2011;**71**(3):124-8.
17. Haukenes G, Aarli JA. [Postviral fatigue syndrome]. *Tidsskr Nor Laegeforen* 1995;**115**(24):3017-22.
18. Gjesdal S, Bratberg E. Diagnosis and duration of sickness absence as predictors for disability pension: results from a three-year, multi-register based* and prospective study. *Scandinavian journal of public health* 2003;**31**(4):246-54.
19. Van Ness J, Stevent S, Bateman L, et al. Postexertional Malaise in Women with Chronic Fatigue Syndrome. *Journal of Women's Health* 2010;**19**(2):239-44.

- 1
- 2
- 3 20. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with
- 4 multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;**46**(10):1121-3.
- 5 21. Lerdal A, Wahl A, Rustoen T, et al. Fatigue in the general population: a translation and test of the
- 6 psychometric properties of the Norwegian version of the fatigue severity scale. *Scandinavian*
- 7 *journal of public health* 2005;**33**(2):123-30.
- 8 22. Mundt JC, Marks IM, Shear MK, et al. The Work and Social Adjustment Scale: a simple measure of
- 9 impairment in functioning. *The British journal of psychiatry : the journal of mental science*
- 10 2002;**180**:461-4.
- 11 23. Andersen MM, Permin H, Albrecht F. Illness and disability in Danish Chronic Fatigue Syndrome
- 12 patients at diagnosis and 5-year follow-up. *J Psychosom Res* 2004;**56**(2):217-29.
- 13 24. Vercoolen JH, Swanink CM, Fennis JF, et al. Prognosis in chronic fatigue syndrome: a prospective
- 14 study on the natural course. *J Neurol Neurosurg Psychiatry* 1996;**60**(5):489-94.
- 15 25. Tiersky LA, DeLuca J, Hill N, et al. Longitudinal assessment of neuropsychological functioning,
- 16 psychiatric status, functional disability and employment status in chronic fatigue syndrome.
- 17 *Applied neuropsychology* 2001;**8**(1):41-50.
- 18 26. Deale A, Husain K, Chalder T, et al. Long-term outcome of cognitive behavior therapy versus
- 19 relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. *The American*
- 20 *journal of psychiatry* 2001;**158**(12):2038-42.
- 21 27. Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue
- 22 syndrome: a multicentre randomised controlled trial. *Lancet* 2001;**357**(9259):841-7.
- 23 28. Bentall RP, Powell P, Nye FJ, et al. Predictors of response to treatment for chronic fatigue
- 24 syndrome. *The British journal of psychiatry : the journal of mental science* 2002;**181**:248-52.
- 25 29. McDermott C, Richards SC, Ankers s, et al. An evaluation of a chronic fatigue lifestyle
- 26 management programme focusing on the outcome of return to work or training. *British*
- 27 *Journal of Occupational Therapy* 2004;**67**(6):269-73.
- 28 30. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a
- 29 systematic review. *Qjm* 1997;**90**(3):223-33.
- 30 31. Markussen S, Roed K, Rogeberg OJ, et al. The anatomy of absenteeism. *Journal of health*
- 31 *economics* 2011;**30**(2):277-92.
- 32 32. Lawn T, Kumar P, Knight B, et al. Psychiatric misdiagnoses in patients with chronic fatigue
- 33 syndrome. *JRSM short reports* 2010;**1**(4):28.
- 34 33. Pheley AM, Melby D, Schenck C, et al. Can we predict recovery in chronic fatigue syndrome?
- 35 *Clinical & Health Affairs* 1999;**82**:52-56.
- 36 34. van der Werf SP, de Vree B, Alberts M, et al. Natural course and predicting self-reported
- 37 improvement in patients with chronic fatigue syndrome with a relatively short illness
- 38 duration. *J Psychosom Res* 2002;**53**(3):749-53.
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Table 1 Symptoms on Contac1 and Contac2

	Contact 1	Contact 2	p
FSS score, mean (SD)	6.4 (.96)	5.0 (1.9)	<.001
Headache	61 (71)	47 (52)	.033
Myalgia	65 (72)	52 (58)	.042
Arthralgia	43 (48)	38 (42)	.45
Sleep disturbances	60 (66)	47 (52)	.048
Depression	30 (33)	25 (28)	.42
Concentration problems	83 (92)	58 (64)	<.001
Memory problems	72 (79)	51 (56)	<.001
Sore throat	48 (53)	34 (37)	.008
Tender cervical lymph nodes	17 (19)	30 (33)	.36

FSS: Fatigue Severity Score

SD: Standard deviation

Table 2 FSS score >5 or <5 on second follow-up (Contact 2) and symptoms at Contact 1

	Number of patients	FSS<5	FSS>5	P
Males	30	9 (25)	21 (39)	.17
Females	60	27 (75)	33 (61)	
Age debut of CFS		23.8 (7.9)	24.1 (7.0)	.85
Age (second control)		33.6 (7.9)	35.8 (6.9)	.17
<i>First control (Contact 1)</i>				
Age (first control)		26.8 (7.5)	29.3 (7.0)	.11
FSS score (mean)		6.3 (1.2)	6.4 (.8)	.63
Duration of CFS (yearssum , mean)		3.3 (2.4)	5.6 (4.5)	.006
Arthralgia	89	11 (33)	32 (59)	.010
Myalgia	89	24 (69)	40 (74)	.57
Headache	89	25 (71)	38 (70)	.92
Sleeping disturbances	90	23 (64)	36 (67)	.79
Depression	89	8 (23)	22 (41)	.081
Concentration problems	89	32 (91)	50 (93)	.84
Memory problems	90	30 (83)	41 (76)	.40
Sore throat	90	22 (61)	26 (48)	.23
Tender cervical lymph nodes	90	13 (36)	19 (35)	.93
Psychic stress: effect on fatigue	70			.94
None		1 (3)	1 (3)	
Worse		11 (38)	14 (35)	
Much worse		17 (59)	25 (63)	
<i>Clinical change prior to first control</i>	71			.06
Improvement		16 (55)	12 (29)	
No change		4 (14)	13 (31)	
Worsening		9 (31)	17 (40)	
<i>Education</i>	89			.08
Primary school		2 (6)	7 (13)	
High school		6 (17)	17 (32)	
College or university		28 (78)	29 (55)	

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

Table 3 FSS score >5 or <5 on second follow-up and symptoms at ContactContact 2

	Number of patients	FSS<5	FSS>5	P
Age (second control)	92	33.6 (7.9)	35.8 (6.9)	.17
Duration of CFS (years, mean)	90	10.1 (3.1)	12.1 (4.7)	.028
Arthralgia	90	7 (19)	31 (57)	<.001
Myalgia	90	11 (31)	41 (76)	<.001
Headache	90	11 (31)	35 (65)	.001
Sleeping disturbances	90	9 (25)	37 (69)	<.001
Depression	90	4 (11)	20 (37)	.006
Concentration problems	90	14 (39)	43 (80)	<.001
Memory problems	90	12 (33)	38 (70)	.001
Sore throat	90	12 (33)	22 (41)	.48
Tender cervical lymph nodes	90	6 (17)	24 (44)	.006

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

**Table 4 Linear regression with WSAS
as dependent variable and variables
registered at Contact 1**

	Beta	P-value
Sex	<.001	1.0
Age	.16	.17
Depression	.27	.026
Arthralgia	.25	.041
Clinical change	-.26	.031
Psychic stress	-.28	.025
Education	-.27	.021

WSAS: Work and Social Adjustment Scale

Table 5 Longitudinal assessment of employment status in chronic fatigue syndrome

Source	Intervention	Time of follow-up months	Patients evaluated for work status No	Patients employed at baseline/follow-up No
Andersen et al ²³	None	60	33	23/9
Vercoulen et al ²⁴	None	18	246	28/29
Tiersky et al ²⁵	None	42	35	32/23
McDermott et al ²⁹	LMP	18	74	0/42
Deale et al ²⁶	CBT	60	25	a)
Prins et al ²⁷	CBT	14	58	b)

LMP: Life Management Program, occupational therapy.

CBT: Cognitive Behaviour Therapy

a): similar proportions of patients in CBT group (56%) versus relaxation therapy control group (39 %) were employed at 5 year follow-up. CBT group patients worked more hours per week, 36 versus 24

b): hours working in a job were similar in the CBT group and the natural course control group

1
2
3 **Figure 1 Employment status of patients with CFS at first contact (Contact 1)**
4
5 **and follow-up (Contact 2)**
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Longitudinal follow up of employment status in patients with chronic fatigue syndrome after mononucleosis

Morten Nyland¹ cand. polit., Halvor Naess^{1,2*} MD, Jon Steinar Birkeland² MD, Harald Nyland¹ MD

¹ Institute of clinical medicine, University of Bergen, Bergen, Norway

² Department of Neurology, Haukeland University Hospital, Bergen, Norway

* Corresponding author

haln@haukeland.no

Department of Neurology

Haukeland University Hospital

Jonas Liesgt 65

5021 Bergen

Norway

Telephone: +4755975045

Fax: +4755975699

Key words: chronic fatigue syndrome, mononucleosis, prognosis, employment

Word count: 3410

Field Code Changed

Abstract

Objective - To examine the effect of early clinical and demographic factors on occupational outcome, return to work or awarded permanent disability pension in young patients with chronic fatigue syndrome (CFS).

Design - Longitudinal cohort study.

Intervention - A written self-management program including a description of active coping strategies for daily life was provided.

Setting, participants - Patients with CFS after mononucleosis were evaluated at Department of Neurology, Haukeland University Hospital during 1996-2006 (Contact 1). In 2009 self-report questionnaires were sent to all patients (Contact 2).

Primary and secondary outcome measures - Primary measure was employment status at Contact 2. Secondary measures included clinical symptoms, and Fatigue Severity Scale (FSS) scores on both contacts, and Work and Social Adjustment Scale (WSAS) at Contact 2.

Results - Of 111 patients at Contact 1, 92 (83%) patients returned the questionnaire at Contact 2. Mean disease duration at Contact 1 was 4.7 years and at Contact 2 11.4 years. At Contact 1, 9 (10%) were part or full time employed. At Contact 2, 49 (55%) were part or full time employed. Logical regression analysis showed that $FSS \geq 5$ at Contact 2 was associated with depression, arthralgia, and long disease duration (all at Contact 1).

Conclusion - About half of younger CFS patients with long-term incapacity for work experienced marked improvement including full or part-time employment showing better outcomes than expected. Risk factors for transition to permanent disability were depression, arthralgia and disease duration.

1
2
3
4
5
6
7 **Article summary**
8

9 *Strengths and limitations of this study*
10

11 Two strengths of the study are very long prospective follow up period and focus on
12 employment.
13

14
15 A limitation is that patients were recruited from a tertiary center.
16

17
18 Long-term prognosis for young patients with CFS after mononucleosis is favorable for a large
19 subgroup.
20

21
22 More than half of the patients with long-term incapacity for work are re-employed after mean
23 disease duration of 11.4 years.
24

25
26 Factors associated with poor long-term prognosis include depression, arthralgia and disease
27 duration.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Chronic fatigue syndrome (CFS) is a complex incapacitating illness of unknown cause.^{1,2} CFS is characterized by persistent/recurrent post-exertional fatigue of at least 6 months' duration accompanied by at least four of eight specific symptoms including impaired short-term memory or concentration, severe enough to cause substantial reduction in previous levels of occupational, educational, social or personal activities; headache of a new type, pattern or severity; muscle pain; multi-joint pain without swelling or redness; sore throat; tender cervical or axillary lymph nodes; unrefreshing sleep; post-exertional malaise, an exaggerated fatigue response to previous well tolerated activities.^{1,3} The clinical condition has received increased attention in the past two decades from medical, psychological and social security/insurance communities. The term ``Chronic Fatigue Syndrome`` was coined in 1988 by the US ~~Centers~~res for Disease Control (CDC) and the present case definition was developed by a joint CDC/National Institute of Health (NIH) international working group.¹ The excessive fatigue and fatigue-ability with disproportionately prolonged recovery after ~~exercise~~exercise or activity differentiate CFS from other fatigue conditions.

Recent population-based epidemiologic studies using the 1994 ~~Centers for Disease Control-CDC~~ case definition have reported the overall CFS prevalence to be 71 and 190 per 100,000 persons, respectively in Olmsted County, Minnesota and three regions of England.^{4,5} CFS occurs in individuals during peak years of employment (age 20-50) with female preponderance. Rates of unemployment are high.⁶ Work-related physical and cognitive impairments are demonstrable with prolongation and recurrence of sickness absence episodes that can be the first step in a process leading to prolonged medical leave and awarded disability benefits.⁷

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A small proportion of people that develop infectious mononucleosis remain sick with CFS.⁸ A recent follow-up study of the course and outcome of CFS in adolescents after mononucleosis showed that most individuals recover; however 13 of 301 adolescents, 4% , all female, met the criteria of CFS after 2 years.⁹

Field Code Changed

Knowledge about the natural history and prognostic factors in CFS is important as it relates to several aspects of the illness; information and advice to newly diagnosed patients, planning of health care and rehabilitation strategies that focus on volitional and social aspects of re-employment.¹⁰ Being unable to fulfill valued and expected social functions, including employment, can have a dramatic impact on ~~their~~ self-concept with need to re-evaluate life goals, as well as increased stress on the part of caregivers.¹¹

Field Code Changed

Few patient-based longitudinal studies have examined employment outcomes as measure of prognosis in the case of CFS.^{12 13} The objectives of this ~~prospective two time point~~ study of a cohort of younger CFS patients without systematic intervention were to document the natural course of illness and to identify predictors of work cessation or re-entry into work force. Only patients with CFS subsequent to mononucleosis were included in this study. ~~The patients were given a written self-management program including a description of active coping strategies for daily life. A small proportion of people that develop infectious mononucleosis remain sick with CFS.⁸ A recent follow-up study of the course and outcome of CFS in adolescents after mononucleosis showed that most individuals recover; however 13 of 301 adolescents, 4% , all female, met the criteria of CFS after 2 years.⁹~~

Field Code Changed

1
2
3
4
5
6
7 We hypothesized that baseline clinical presentations such as cognitive problems,
8 pain and depression at the time of referral in addition to severe fatigue and long
9 illness duration prior to the evaluation predict long-term functional disability
10 including unemployment and awarded disability benefits.
11
12
13
14
15
16
17
18
19

20 **Material and methods**

21 *Patients*

22
23
24
25 The 111 young patients, mean age 23 year, participating in this study were part of
26 a larger cohort of 873 consecutive patients referred from all over Norway to a
27 specialist chronic fatigue clinic at the Department of Neurology, Haukeland
28 University Hospital during 1996-2006, published previously.¹⁴ All patients were
29 interviewed and examined by a specialist physician, HIN, who confirmed the
30 diagnosis of CSF meeting the Centers for Disease Control and Prevention (CDC)
31 case definition.¹ The 111 patients constitute all patients diagnosed with CSF
32 triggered by mononucleosis in the total cohort of 873 patients. The diagnosis of
33 mononucleosis was based on the physician report following the patient to our
34 clinic.
35
36
37
38
39
40
41
42
43
44

45 ~~All received information about the illness to provide the patients with a rationale~~
46 ~~and structured meaning for their illness experience.~~—A written self-managment
47 program included information about the illness to provide the patients with a
48 rationale and structural meaning for their illness experience.¹⁵ Active coping
49 strategies for daily life included graded activity planning; encouraging activity,
50
51
52
53
54

1
2
3
4
5
6
7 but staying within their physical limitations with consistent rest periods to
8 minimize fluctuations in fatigue and symptoms. To avoid occupational
9 impairment and restore ability to work the importance to keep contact with the
10 local health and rehabilitation services, and inform the employer was stressed. The
11 family doctor and the local National Sickness Benefit Scheme office (NAV)
12 received a specialist report on the medical history and investigations, the clinical
13 characteristics and disability.¹⁶

14
15
16
17
18
19
20
21 The Norwegian Social and Insurance Scheme accepted CFS as a medico-legal
22 diagnosis entitled to sickness and disability benefits to compensate for income
23 loss in 1995.¹⁷ To receive long-term sickness absence (SA) benefits a sickness
24 certificate has to be issued by a physician describing the cause of absence and
25 plans for treatment. A disability pension (DP) is given to individuals aged 18 to
26 66 to compensate for permanent work-life exit before scheduled age retirement
27 after relevant treatment or vocational rehabilitation.¹⁸

28
29
30
31
32
33
34
35 Primary outcome measures at long-term follow-up were employment: return to
36 part- or full-time work, or transition to ill-health retirement and receipt of
37 permanent disability pension. Secondary outcomes were self-rated scales of
38 clinical change, fatigue, disability and CFS somatic symptoms.

39 40 41 42 43 *Contact 1. Initial baseline evaluation*

44
45
46 All patients completed a questionnaire at referral that included questions about the
47 mode of clinical onset (whether the fatigue appeared acutely or evolved gradually
48 over months) and duration of the illness. Questions about presenting symptoms
49 comprised the presence or not of concentration or memory problems, throat pain,
50 enlarged or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia,
51
52
53
54
55

1
2
3
4
5
6
7 weight change, frequent micturition, photophobia, slurred vision, dizziness,
8
9 tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever,
10
11 increased sweating and headache. Post-exertional malaise (PEM)¹⁹ was assessed
12
13 with the following question: does physical activity influence fatigue; improving,
14
15 no effect, some worsening, much worsening?

16
17 Fatigue was self-rated by the Fatigue Severity Scale (FSS).²⁰ This is a 9- item
18
19 questionnaire that assesses the effect of fatigue on daily living. Each item is a
20
21 statement on fatigue that the subject rates from 1, “completely disagree” to 7,
22
23 “completely agree”. Examples of the items in the questionnaire are: “My
24
25 motivation is lower when I am fatigued”, “Exercise brings on my fatigue” and “I
26
27 am easily fatigued”. The average score of the 9 items represents the FSS score
28
29 (minimum score is 1 and maximum score is 7). Patients with a mean FSS score >5
30
31 are defined as having severe fatigue.²¹

32
33 Employment status was noted as employed full-time, part-time or unemployed.
34
35 Sick leave from work or study, long term SA benefits and DP were registered.
36
37 Employment or studies at the time of the triggering mononucleosis were
38
39 registered.

40 41 *Contact 2. Follow-up during 2009*

42
43
44 Self-report questionnaires were sent to the patients in 2009 on average 6.5 years
45
46 after Contact 1. A clinical symptom questionnaire included questions as to
47
48 presence or not of problems with concentration and memory, throat pain, enlarged
49
50 or tender lymph nodes, myalgia, muscle weakness, arthralgia, dyspepsia, nausea,
51
52 weight change, frequent micturition, photophobia, slurred vision, dizziness,
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 tinnitus, sleep disturbances, depression, unstable mood, palpitations, fever,
8 increased sweating and headache.
9

10 The Work and Social Adjustment Scale (WSAS) was used to measure disability.

11 It is a five-item scale that assesses an individual's ability to perform everyday
12 activities including work, home management, family and relationship interaction,
13 and social and private leisure activities. Each of the five items was rated on a 9-
14 point scale ranging from 0 (not at all a problem) to 8 (severely impaired) so that
15 the total scores range between 0 and 40.²² The psychometric properties have been
16 validated in large CFS patient cohorts confirming that WSAS is a reliable
17 assessment tool for disability. High scores correlate with severe fatigue and poor
18 physical fitness.¹⁶
19
20
21
22
23
24
25
26
27

28
29 Fatigue was self-rated by the ~~FSS~~FSS scale. Based on change in FSS score change
30 from baseline, Contact 1, the disease course was defined; FSS change <-1 was
31 defined as worsening course; FSS change ≥ -1 and ≤ 1 was defined as no change;
32 FSS change >1 was defined as improvement. Self-rated global clinical outcome
33 was scored as worsening, stable, improvement and recovered. Employment status,
34 sickness and disability benefits were recorded providing objective evidence of
35 disability. ~~Outcome questions included the patients' rating of overall worsening or~~
36 ~~improvement, and employment or disability benefit status.~~
37
38
39
40
41
42
43
44

45 The study was approved by the local ethics committee. Informed, written consent
46 was obtained from the patients.
47
48
49

50 *Statistics*

51
52 Student's t-test, chi-square test, Fisher's exact test, and pair-wise correlation test
53 were performed when appropriate. The ~~FSS~~FSS score was dichotomized and ~~FSS~~FSS
54
55
56
57
58
59
60

1
2
3
4
5
6
7 score \geq 5 defined as pathological fatigue. Stepwise backward logistic regression
8 analyses were performed with dichotomized FSS score at Contact 2 as dependent
9 variable. Stepwise backward linear regression analyses with FSS at Contact 2 and
10 WSAS as dependent variables were performed. STATA 12.0 was used for
11 analyses.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 Results

28
29
30 In total, 111 patients participated in the baseline evaluation (~~Contact 1~~). Postal
31 questionnaires were completed and returned by 92 (83%) of these patients on
32 follow-up (Contact 2); 30 (33%) males and 62 (67%) females (Contact 2). The
33 mean age of the patients at the onset of CFS was 23.7 years (SD 7.3). Mean
34 duration of CFS at the time of Contact 1 was 4.7 years (SD 4.0), (median 3.2
35 years, inter-quartile range (IQR) 1.9 – 6.4). Mean time from debut of CFS
36 to Contact 2 was 11.4 years (SD 4.3) (median 10.3 years, IQR 8.5 – 13.5) (range
37 4.7 – 23.8). At the time of mononucleosis 43 (47%) were employed at work and
38 48 (52%) were students (missing data in one patient). We do not report any data
39 on the 19 (17%) who did not complete the follow-up.
40
41
42
43
44
45
46
47
48
49

50 *Employment at Contact 1 (92 patients)*
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 At Contact 1 nine (10.2%) patients remained employed (1 full time and 8 part
8 time), 12 patients (13.5%) were students and 70 patients (81%) were neither
9 employed nor studying (missing data in one patient). One patient (1%) was
10 receiving partial DP and 7 patients (8%) were receiving full DP. Fourteen (15%)
11 patients received partial long-term ~~sickness-absence~~SA benefits, and 62 (67%)
12 patients received full long-term sickness ~~absence-benefits~~SA (missing data in 8
13 patients).
14
15
16
17
18
19

20
21 *Employment at Contact 2(primary measures)(92 patients)*
22

23 At Contact 2 twenty-four (27%) were fully employed, 25 (28%) were employed
24 part-time and 40 (45%) were unemployed (missing data in three patients). One
25 patient (1%) was student. In total, 63 of 92 patients received DP or sickness
26 absence benefits:Fifteen-15 patients (17%) were awarded partial DP and 39 (44%)
27 received full DP for the reduced working capacity. ~~Six-6~~ patients (7%) got partial
28 ~~sickness-absence~~SA benefits and 3 patients (3%) full ~~sickness-absence~~SA benefits.
29
30
31
32
33
34 One (1%) unemployed patient was part time student. Five (5%) patients were
35 employed at both Contact 1 and Contact 2. Figure 1 shows employment status at
36 Contact 1 and Contact 2.
37
38
39

40
41 Logistic regression analyses showed that being employed at ~~at~~ Contact 2 was
42 associated with lack of arthralgia (OR=.3, P=.028) and reporting improvement
43 (OR=1.8, P=.062) ~~at~~ ~~Contact~~ Contact 1. Another logistic regression analyses
44 showed that being employed at Contact 2 was associated with low FSS score ~~at~~
45 Contact 2 (OR=.53, P<.001), lack of arthralgia (OR=.40, P=.041), and lack of
46 concentration problems (OR=.32, P=.064), but none of the other symptoms
47 reported at Contact 2.
48
49
50
51
52
53
54
55

Secondary measures

There was no correlation between FSS score at Contact 2 and degree of PEM at Contact 1 (P=.57). There was no correlation between mode of onset of fatigue after mononucleosis (acute or taking months) and FSS score at Contact 2 (P=.61). Neither was there any correlation between employment status at Contact 2 and degree of PEM at Contact 1 (P=.91) nor mode of onset (P=.59). There was no correlation between degree of PEM at Contact 1 and FSS score at Contact 1 (P=.99).

Based on FSS change from Contact 1 to Contact 2, 38 (44%) (FSS improvement >1) improved, 42 (48%) (FSS change ≤ 1 and ≥ -1) did not change and 7 (8%) worsened (FSS change <-1). Based on self-assessment 10 (12%) had worsened, 14 (17%) were stable, 47 (57%) had improved and 11 (13%) had recovered at Contact 2.

The correlation between self-rated clinical change between Contact 1 and Contact 2 and employment status at Contact 2 was $r = .54$ (P<.001). The correlation between change in FSS from Contact 1 to Contact 2 and employment status was $r = .30$ (P=.01). The correlation between FSS score at Contact 2 and employment was $r = .51$ (P<.001). The correlation between WSAS score and employment was $r = .74$ (P<.001). The correlation between WSAS score and FSS score at Contact 2 was $r = .81$ (P<.001).

Clinical characteristics based on evaluation at Contact 1 and Contact 2 are shown in Table 1. Mean FSS score dropped from 6.4 to 5.0 (P<.001). CFS symptom pattern showed significant less frequencies of concentration and memory problems, headache, myalgia, sleep disturbances at Contact 2 compared to

1
2
3
4
5
6
7 Contact 1 (all $P < .005$), but no changes as to depression and arthralgia. A
8 comparison between patients with $FSS \geq 5$ versus $FSS < 5$ at Contact 2 is shown in
9 Table 2 and 3.
10

11
12
13 Among 26 patients who reported improvement prior to Contact 1, 25 (96%)
14 reported further improvement at Contact 2, whereas among 38 patients who
15 reported worsening or no change at Contact 1, 23 (61%) reported improvement at
16 Contact 2 ($P = .001$).
17
18
19

20
21 Logistic regression showed that $FSS \geq 5$ (versus $FSS < 5$) at Contact 2 was
22 associated with the following variables registered at Contact 1: arthralgia (OR=
23 3.1, $P = .026$), depression (OR=4.0, $P = .029$), duration of disease (OR=1.2, $P = .043$),
24 and male sex (OR=2.6, $P = .087$). Linear regression analysis with FSS score at
25 Contact 2 as dependent variable showed that arthralgia, depression (both at
26 Contact 1) and level of education accounted for 22% of the variation of the FSS
27 score (R -squared = .22).
28
29
30
31
32
33
34

35
36 Disability was evaluated according to the WSAS, and [Table 4](#) shows linear
37 regression with WSAS score as dependent variable and variables registered at
38 Contact 1. WSAS score was significantly associated with depression, arthralgia,
39 clinical change, psychic stress and level of education (R -squared=.28)
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Discussion

Our main finding was that about half of the patients improved during the study period and were fully or partly employed at the final follow-up. This shows that the occupational outcome is favorable in a considerable fraction of younger CFS patients after on average 5 years sickness absence from work. However, the transition to partly (15 patients) or full (39 patients) permanent disability pension shows that a substantial proportion develop chronic incapacity for work with severe negative consequences both for the individual and for the wider society and economy.

Few studies have examined employment status over time using operational criteria for CFS and standardized measurements of disability and functioning to

1
2
3
4
5
6
7 provide information about the numbers of patients who were functionally
8 impaired and unable to work.¹³ To our knowledge this study is the longest follow-
9 up study of CFS that has been published. Table 5 describes 6 studies that
10 examined work status over time. ~~Another~~ long-term follow-up study included 33
11 patients, mean age 43 year, who answered identical questionnaires at diagnosis,
12 after 4 years illness duration, and 5 years later. Work disability was very high at
13 baseline (77%) and increased to 91 % at 5-year follow-up.²³ A prospective study
14 including 246 patients found little improvement in occupational status after a
15 follow-up period of 18 months. Before onset of complaints 141 (57%) patients
16 worked. At initial assessment 69 (28%) worked and 105 (43%) were on sick leave
17 or receiving disability benefits. At follow-up 71 patients (29%) worked and 103
18 (42%) were on sick leave. Self-reported improvement was indicated by 50
19 patients (20%), and 49 (20%) reported worsening of complaints.²⁴ Another study
20 reported the outcome for 35 CFS patients ~~(mean age 35 years)~~ evaluated 42
21 months after the initial visit. Higher unemployment rates were found at follow-up;
22 77% of patients versus 68% at baseline assessment.²⁵

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 A few longitudinal studies have reported employment at baseline and follow-up
39 after intervention. A long-term study of cognitive behavior therapy versus
40 relaxation therapy evaluated outcome at 5-year follow-up. A total of 68% of the
41 25 patients who received cognitive therapy rated themselves as improved
42 compared to 36% of the 28 patients who received relaxation therapy. Similar
43 proportions of patients were employed (56% versus 39%) but the patients in the
44 cognitive behavior group worked more hours per week (36 versus 24).²⁶ ~~In~~
45 ~~another study, cognitive behavior therapy was compared with a guided support~~
46 ~~group and a natural course group at baseline and 14 months follow up. Self rated~~

1
2
3
4
5
6
7 improvement was recorded in 28/58 (50%) in the cognitive therapy group versus
8 ~~24/76 (32%) in the natural course group. However, In another study~~ no treatment
9 effect of cognitive behavior therapy as compared to natural course was found on
10
11 work rehabilitation, ~~only hours working in a job were measured although self-~~
12
13 ~~rated improvement was associated with cognitive behavior treatment.~~²⁷
14
15

16
17 A randomized controlled trial of patient education to encourage graded exercise
18
19 resulted in substantial self-reported improvement in physical and occupational
20
21 functioning compared with standard medical care. The receipt of sickness benefit
22
23 at the start of treatment was associated with poor outcome.²⁸ Occupational
24
25 therapy with a lifestyle management program was offered to 74 patients after
26
27 median illness duration of 5 years. At follow-up 18 months later 31 (42%) of the
28
29 patients had returned to new employment, voluntary work or training.²⁹
30

31
32 A comprehensive review of the literature on the natural course of CFS shows
33
34 that the illness runs a chronic course in many sufferers and that less than 10% of
35
36 subjects return to pre-morbid levels of functioning.³⁰ ~~A substantial improvement~~
37
38 ~~has, however, been observed in younger individuals. A recent study describes~~
39
40 ~~variation in the CFS clinical phenotype in a group of younger patients as~~
41
42 ~~compared to those older than 50. In addition to the observed generally positive~~
43
44 ~~outcome for young people that study shows that CFS is a heterogeneous condition~~
45
46 ~~of complex and multifactorial etiology.~~⁶ Return to work after long-time sickness
47
48 absence is a complex process influenced by the severity of the disorder, personal
49
50 factors, work-related factors and the compensation system.

51
52 We found that all patients who were unemployed at the initial examination
53
54 received sickness or disability benefits. Norway has been criticized for high
55
56

Field Code Changed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

disability payments which may undermine motivation for individuals to stay in work.³¹ A poor response to treatment for CFS was predicted by being in receipt of sickness benefits in a patient education study.²⁸ In contrast, this study shows that long-term compensations to secure the socio-economic position does not inhibit return to work, but may be essential contributors to the high proportion becoming employed at final follow-up. In addition to the financial support the contact with the social security system initiates -rehabilitation -activities directed towards obtaining new work when unemployed.¹⁸

It is important to disclose predictors for long-term outcome as this may suggest targets for management. We found that arthralgia at the first contact independently predicted poor long-term prognosis as evaluated by employment, FSS and WSAS scores. Arthralgia is a prominent and serious somatic symptom in the majority of CFS patients.⁴ ~~One may speculate that some patients with arthralgia have underlying atypical chronic rheumatic disease which has not been diagnosed. This suggests that CFS patients with arthralgia may need repeated evaluation as to possible rheumatic disease.~~

We found that depression at the first contact tended to predict poor prognosis both as to FSS and WSAS scores, but not employment. Pre-existing depression is an exclusion criterion of CFS, but many patients develop co-morbid depression reactive to the chronic illness that may contribute to a poorer prognosis due to reduced illness coping.³² In contrast to our findings another study comprising 177 patients did not find any association between depression and final outcome.³³

We found that FSS score at the second contact was associated with duration of illness disease at the first contact. This is compatible to the findings in a study of

1
2
3
4
5
6
7 natural course in CFS. ³⁴ ~~However, there was no significant change as to~~
8 ~~depression, arthralgia or tender lymph nodes.~~
9

10
11 As shown above reviews on predictors of prognosis show conflicting results.¹³

12
13 This may be due to major differences between studies. Important differences
14 include varying number of patients, severity of disease, patient heterogeneity and
15 length of follow-up. Two strengths of the present study are the long-follow up
16 period and the relatively high response rate as to the return of the postal
17 questionnaire including details about occupational status.

18
19 This study differs from
20 most others because mononucleosis was a uniform trigger of CFS in all patients.

21
22 One limitation of the study is that the patients were recruited from a tertiary center
23 and the patient cohort may represent some selection bias. Whether the written
24 self-management program contributed to better outcome than expected is possible.
25
26
27
28
29

30 This should be addressed in controlled studies in the future.

31
32
33 In conclusion, about half of younger CFS patients with long-term incapacity for
34 work got marked improvement including full or part-time employment. Self-
35 management strategies, long-term sickness absence benefits providing a stable
36 financial support, in addition to occupational interventions aimed at return to work
37 were likely contributors to the generally positive, prolonged outcome. Risk factors
38 for transition to permanent disability pension were depression, persistence of
39 arthralgia and disease duration.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Contributor statement:

Morten Nyland: Data collection and manuscript preparation

Halvor Naess: Manuscript preparation and performing of analyses

Jon S Birkeland: Data collection and manuscript preparation

Harald Nyland: Data collection and manuscript preparation

Acknowledgements: none

Competing interests: none

1
2
3
4
5
6
7 Funding: none

8
9 The study was approved by the local ethics committee.

10
11 Data sharing is available by emailing Halvor Naess haln@haukeland.no
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 References

- 34
35
36 | 1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its
37 definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med*
38 1994;**121**(12):953-9.
39 2. Salit IE. Precipitating factors for the chronic fatigue syndrome. *J Psychiatr Res* 1997;**31**(1):59-65.
40 3. Reeves WC, Lloyd A, Vernon SD, et al. Identification of ambiguities in the 1994 chronic fatigue
41 syndrome research case definition and recommendations for resolution. *BMC health services*
42 research 2003;**3**(1):25.
43 4. Vincent A, Brimmer DJ, Whipple MO, et al. Prevalence, incidence, and classification of chronic
44 fatigue syndrome in Olmsted County, Minnesota, as estimated using the Rochester
45 Epidemiology Project. *Mayo Clin Proc* 2012;**87**(12):1145-52.
46 5. Nacul LC, Lacerda EM, Pheby D, et al. Prevalence of myalgic encephalomyelitis/chronic fatigue
47 syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary
48 care. *BMC medicine* 2011;**9**:91.
49 6. Wilson A, Hickie I, Hadzi-Pavlovic D, et al. What is chronic fatigue syndrome? Heterogeneity within
50 an international multicentre study. *The Australian and New Zealand journal of psychiatry*
51 2001;**35**(4):520-7.
52 7. Marmot M, Feeney A, Shipley M, et al. Sickness absence as a measure of health status and
53 functioning: from the UK Whitehall II study. *J Epidemiol Community Health* 1995;**49**(2):124-
54 30.
55
56
57
58
59
60

Formatted: Font: Calibri, Do not check spelling or grammar

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

8. White PD, Thomas JM, Amess J, et al. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever. *The British journal of psychiatry : the journal of mental science* 1998;**173**:475-81.
9. Katz BZ, Shiraishi Y, Mears CJ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. *Pediatrics* 2009;**124**(1):189-93.
10. Taylor RR, Kielhofner GW. Work-related impairment and employment-focused rehabilitation options for individuals with chronic fatigue syndrome: A review. *Journal of Mental Health* 2005;**14**(3):253-67.
11. Ware NC. Sociosomatics and illness in chronic fatigue syndrome. *Psychosomatic medicine* 1998;**60**(4):394-401.
12. Ross SD, Estok RP, Frame D, et al. Disability and chronic fatigue syndrome: a focus on function. *Arch Intern Med* 2004;**164**(10):1098-107.
13. Cairns R, Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. *Occupational medicine* 2005;**55**(1):20-31.
14. Naess H, Sundal E, Myhr KM, et al. Postinfectious and chronic fatigue syndromes: clinical experience from a tertiary-referral centre in Norway. *In vivo* 2010;**24**(2):185-8.
15. Nijs J, Paul L, Wallman K. Chronic fatigue syndrome: an approach combining self-management with graded exercise to avoid exacerbations. *J Rehabil Med* 2008;**40**(4):241-7.
16. Cella M, Sharpe M, Chalder T. Measuring disability in patients with chronic fatigue syndrome: reliability and validity of the Work and Social Adjustment Scale. *J Psychosom Res* 2011;**71**(3):124-8.
17. Haukenes G, Aarli JA. [Postviral fatigue syndrome]. *Tidsskr Nor Laegeforen* 1995;**115**(24):3017-22.
18. Gjesdal S, Bratberg E. Diagnosis and duration of sickness absence as predictors for disability pension: results from a three-year, multi-register based* and prospective study. *Scandinavian journal of public health* 2003;**31**(4):246-54.
19. Van Ness J, Stevent S, Bateman L, et al. Postexertional Malaise in Women with Chronic Fatigue Syndrome. *Journal of Women's Health* 2010;**19**(2):239-44.
20. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;**46**(10):1121-3.
21. Lerdal A, Wahl A, Rustoen T, et al. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. *Scandinavian journal of public health* 2005;**33**(2):123-30.
22. Mundt JC, Marks IM, Shear MK, et al. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. *The British journal of psychiatry : the journal of mental science* 2002;**180**:461-4.
23. Andersen MM, Permin H, Albrecht F. Illness and disability in Danish Chronic Fatigue Syndrome patients at diagnosis and 5-year follow-up. *J Psychosom Res* 2004;**56**(2):217-29.
24. Vercoulen JH, Swanink CM, Fennis JF, et al. Prognosis in chronic fatigue syndrome: a prospective study on the natural course. *J Neurol Neurosurg Psychiatry* 1996;**60**(5):489-94.
25. Tiersky LA, DeLuca J, Hill N, et al. Longitudinal assessment of neuropsychological functioning, psychiatric status, functional disability and employment status in chronic fatigue syndrome. *Applied neuropsychology* 2001;**8**(1):41-50.
26. Deale A, Husain K, Chalder T, et al. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. *The American journal of psychiatry* 2001;**158**(12):2038-42.
27. Prins JB, Bleijenberg G, Bazelmans E, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. *Lancet* 2001;**357**(9259):841-7.
28. Bentall RP, Powell P, Nye FJ, et al. Predictors of response to treatment for chronic fatigue syndrome. *The British journal of psychiatry : the journal of mental science* 2002;**181**:248-52.
29. McDermott C, Richards SC, Ankers s, et al. An evaluation of a chronic fatigue lifestyle management programme focusing on the outcome of return to work or training. *British Journal of Occupational Therapy* 2004;**67**(6):269-73.

Formatted: Font: Calibri, Do not check spelling or grammar

Formatted: Norwegian (Bokmål)

Formatted: Font: Calibri, Do not check spelling or grammar

- 1
2
3
4
5
6
7 30. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a
8 systematic review. *Qjm* 1997;**90**(3):223-33.
9 31. Markussen S, Roed K, Røgeberg OJ, et al. The anatomy of absenteeism. *Journal of health*
10 *economics* 2011;**30**(2):277-92.
11 32. Lawn T, Kumar P, Knight B, et al. Psychiatric misdiagnoses in patients with chronic fatigue
12 syndrome. *JRSM short reports* 2010;**1**(4):28.
13 33. Pheley AM, Melby D, Schenck C, et al. Can we predict recovery in chronic fatigue syndrome?
14 *Clinical & Health Affairs* 1999;**82**:52-56.
15 34. van der Werf SP, de Vree B, Alberts M, et al. Natural course and predicting self-reported
16 improvement in patients with chronic fatigue syndrome with a relatively short illness
17 duration. *J Psychosom Res* 2002;**53**(3):749-53.
18
19
20
21
22
23
24
25
26
27

28 **Table 1 Symptoms on Contact1 and Contact2**

	Contact 1	Contact 2	p
FSS score, mean (SD)	6.4 (.96)	5.0 (1.9)	<.001
Headache	61 (71)	47 (52)	.033
Myalgia	65 (72)	52 (58)	.042
Arthralgia	43 (48)	38 (42)	.45
Sleep disturbances	60 (66)	47 (52)	.048
Depression	30 (33)	25 (28)	.42
Concentration problems	83 (92)	58 (64)	<.001
Memory problems	72 (79)	51 (56)	<.001
Sore throat	48 (53)	34 (37)	.008
Tender cervical lymph nodes	17 (19)	30 (33)	.36

45 FSS: Fatigue Severity Score

46 SD: Standard deviation
47
48
49
50
51
52
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 FSS score >5 or <5 on second follow-up (Contact 2) and symptoms at Contact 1

	Number of patients	FSS<5	FSS>5	P
Males	30	9 (25)	21 (39)	.17
Females	60	27 (75)	33 (61)	
Age debut of CFS		23.8 (7.9)	24.1 (7.0)	.85
Age (second control)		33.6 (7.9)	35.8 (6.9)	.17
<i>First control (Contact 1)</i>				
Age (first control)		26.8 (7.5)	29.3 (7.0)	.11
FSS score (mean)		6.3 (1.2)	6.4 (.8)	.63
Duration of CFS (yearssum , mean)		3.3 (2.4)	5.6 (4.5)	.006
Arthralgia	89	11 (33)	32 (59)	.010
Myalgia	89	24 (69)	40 (74)	.57
Headache	89	25 (71)	38 (70)	.92
Sleeping disturbances	90	23 (64)	36 (67)	.79
Depression	89	8 (23)	22 (41)	.081
Concentration problems	89	32 (91)	50 (93)	.84
Memory problems	90	30 (83)	41 (76)	.40
Sore throat	90	22 (61)	26 (48)	.23
Tender cervical lymph nodes	90	13 (36)	19 (35)	.93

Psychic stress: effect on fatigue	70		.94
None		1 (3)	1 (3)
Worse		11 (38)	14 (35)
Much worse		17 (59)	25 (63)
<i>Clinical change prior to first control</i>	71		.06
Improvement		16 (55)	12 (29)
No change		4 (14)	13 (31)
Worsening		9 (31)	17 (40)
<i>Education</i>	89		.08
Primary school		2 (6)	7 (13)
High school		6 (17)	17 (32)
College or university		28 (78)	29 (55)

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

Table 3 FSS score >5 or <5 on second follow-up and symptoms at ContactContact 2

	Number of patients	FSS<5	FSS>5	P
Age (second control)	92	33.6 (7.9)	35.8 (6.9)	.17
Duration of CFS (years, mean)	90	10.1 (3.1)	12.1 (4.7)	.028
Arthralgia	90	7 (19)	31 (57)	<.001
Myalgia	90	11 (31)	41 (76)	<.001
Headache	90	11 (31)	35 (65)	.001
Sleeping disturbances	90	9 (25)	37 (69)	<.001
Depression	90	4 (11)	20 (37)	.006
Concentration problems	90	14 (39)	43 (80)	<.001
Memory problems	90	12 (33)	38 (70)	.001
Sore throat	90	12 (33)	22 (41)	.48
Tender cervical lymph nodes	90	6 (17)	24 (44)	.006

FSS: Fatigue Severity Scale

CFS: Chronic fatigue syndrome

**Table 4 Linear regression with WSAS
as dependent variable and variables
registered at Contact 1**

	Beta	P-value
Sex	<.001	1.0
Age	.16	.17
Depression	.27	.026
Arthralgia	.25	.041
Clinical change	-.26	.031
Psychic stress	-.28	.025
Education	-.27	.021

WSAS: Work and Social Adjustment Scale

Table 5 Longitudinal assessment of employment status in chronic fatigue syndrome

Source	Intervention	Time of follow-up, mo	Patients evaluated work status, No	Patients employed at baseline/follow-up, %
Andersen et al ²³	None	60	33	23/9
Vercoulen et al ²⁴	None	18	246	28/29
Tiersky et al ²⁵	None	42	35	32/23
McDermott et al ²⁹	LMP	18	74	0/42
Deale et al ²⁶	CBT	60	25	a)
Prins et al ²⁷	CBT	14	58	b)

LMP: Life Management Program, occupational therapy.

CBT: Cognitive Behaviour Therapy

a): similar proportions of patients in CBT group (56%) versus relaxation therapy control group (39 %) were employed at 5 year follow-up. CBT group patients worked more hours per week, 36 versus 24.

b): hours working in a job were similar in the CBT group and the natural course control group

Formatted: English (U.S.)


Formatted: English (U.S.)

Formatted: English (U.S.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 Employment status of patients with CFS at first contact (Contact 1) and follow-up (Contact 2)

For peer review only




STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-9
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-9
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	10
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	10-11 10-11
Outcome data	15*	Report numbers of outcome events or summary measures over time	10-12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	17
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



122x67mm (300 x 300 DPI)

review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60